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Resumo 
 
  
 
 Durante as ultimas décadas, transportadores coloidais e inorgânicos têm sido estudados 
na veiculação dérmica/transdérmica de fármacos. O sucesso da implementação destes siste-
mas neste tipo de veiculação prende-se com a sua capacidade de atravessar várias barreiras 
anatómicas, a capacidade de libertar o fármaco de forma controlada e ainda da sua estabili-
dade à escala nanométrica. 
 No início dos anos 90, entre os transportadores coloidais lipídicos surgiram as nanopartí-
culas lipídicas sólidas (SLN) como sistemas bastante promissores na veiculação de fármacos. 
 Por isto, estas nanoparticulas são amplamente aceites por combinar as vantagens e 
ultrapassar as desvantagens associadas a outros transportadores coloidais. Contudo, a baixa 
capacidade de retenção do fármaco e a sua expulsão durante o armazenamento são as suas 
grandes desvantagens. Transportadores lipídicos nanoestruturados (NLC) foram desenvolvidos 
para ultrapassar a baixa capacidade de retenção do fármaco nas SLN, ao diminuir o grau de 
organização da sua matriz lipídica. Baseiam-se numa mistura de lipidos que resulta em várias 
imperfeições na sua matriz promovendo a maior acomodação do fármaco. Como os lípidos 
liquídos exibem maior solubilidade para os fármacos, transportadores lipidicos nanoestrutu-
rados têm maior capacidade de retenção dos fármacos bem como uma libertação mais con-
trolada do mesmo. Várias vias de administração têm sido investigadas para estas nanoparti-
culas de matriz lipídica: tópica, oral ou parental. 
 O metotrexato (MTX) é um antagonista do ácido fólico que se liga competitivamente à 
enzima dihidrofolato redutase que impede o crecimento da célula, retém o ciclo celular nas 
fases G1/S e é utilizado em ensaios clínicos, desde os anos 50, no tratamento de diferentes 
tumores sólidos e ainda na terapida de doenças autoimunes e inflamatórias como a artrite 
reumatóide e psoríase. Para ultrapassar os inconvenientes associdas à terapêutica com MTX 
(por ex. hepatotoxicicidade, colite ulcerativea, nefrotoxicidade), os veiculadores coloidais 
poderão ser aplicados. 
 
 A produção de nanopartículas requer um elevado conhecimento de todos os parâmetros e 
propriedades do processo. Utilizar a abordagem tradicional (um factor de cada vez) para 
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obter uma formulação optimizada é difícil de conceber, ineficiente e bastante morosa. O 
desenho estatístico das formulações é uma estratégia validada e bastante útil na preparação 
de uma formulação com menos ensaios experimentais e, que fornece informação suficiente 
entre as variáveis dependentes e independentes no processo. Alguns estudos descreveram 
nanopartículas lipídicas optimizadas através de um modelo factorial. Neste trabalho, o efei-
to da composição da formulação na optimização de NLCs com MTX foi realizada recorrendo a 
um modelo denominado Box-Behnken. A formulação foi produzida pelo método de ultrasoni-
cação utilizando Witepsol®E85 como lípido sólido e Migliol®812 como lípido liquido e as suas 
propriedades físico químicas (morfologia, tamanho, índice de polidispersão e eficiência de 
incorporação), libertação in vitro do fármaco e viabilidade celular foram estudadas.  As 
NLCs optimizadas exibiram uma forma praticamente esférica, com tamanhos de 252-nm, 
índice de polidispersão de 0.06 ± 0.02, potencial zeta de -14 mV e eficiência de incorporação 
de 87%. Os estudos de libertação mostraram que o fármaco tem uma libertação inicial rápida 
seguida de uma fase controlada durante 24 horas. O modelo matemático de Peppas-
Korsmeyer descreve a cinética desta libertação para ambientes fisiológicos e inflamatórios e 
o modelo Hixson-Crowell nas condições simuladas da pele. Não foi observada citotoxicidade 
em fibroblastos. Assim, NLCs com MTX têm potential para ser exploradas como sistemas vei-
culadores de fármacos. 
 A segunda abordagem do trabalho consistiu no desenvolvimento de um modelo para vei-
culação de fármacos com alvo local de acção para o tratamento da psoríase. Para veicular 
MTX, foram produzidas, NLC e SLN funcionalizadas com Etanercept, anticorpo monoclonal 
comumente usado na terapia biológica da psoríase para assim obter uma terapia direcionada. 
 Estas nanoformulações foram incorporadas num hidrogel para eventualmente facilitar a 
sua penetração na barreira dérmica. A formulação foi produzida pelo método descrito acima, 
utilizando palmitato de cetilo como lípido sólido e Migliol® 812 como lípido líquido e caracte-
rizadas em termos de propriedades físico-quimicas, perfil de libertação do fármaco e citoto-
xicidade em fibroblastos e queratinócitos, ensaios de permeação e propriedades reológicas. 
 Todas as nanoformulações apresentam tamanhos à volta dos 400-nm, potencial zeta de -
30 mV, índice de polidispersão inferior a 0.3 e elevados valores de eficiência de incorporação 
do fármaco. Para além disso, microscopia por TEM e Cryo-SEM mostrou que todas as nanopar-
tículas exibem forma esférica independentemente da sua composição e foram estáveis 
durante 6 semanas, à temperatura ambiente. A libertação do MTX mostrou o mesmo compor-
tamento das formulações anteriores: rápido seguido de um perfil controlado. Para além dis-
so, um hidrogel (Carbopol 934®) foi enriquecido com ambas as nanoparticulas lipídicas com e 
sem MTX, e a mesma combinação das nanopartículas funcionalizadas. Análises reológicas 
revelaram que estas nanoformulações possuem comportamento não-Newtoniano, pseudoplás-
tico e tixotropia, sugerindo que são apropriadas para veiculação tópica. No entanto, possuem 
uma ligeira perda de consistência após 2 semanas de preparação. Ensaios de permeação da 
iii 
 
pele demonstraram, mimetizando condições fisiológicas, as nanopartículas lipídicas com MTX 
possuem bons níveis de penetração do fármaco e proteína funcionalizada, através da pele de 
porco. Observa-se um pequeno decréscimo quando as nanopartículas são incorporados no 
hidrogel. 
 Os principais resultados obtidos para ambas as nanopartículas permitem afirmar que pos-
suem propriedades interessantes para veicular MTX. Estes resultados revelam ainda que estes 
sistemas são uma plataforma promissora para a terapia tópica de doenças inflamatórias, 
como a psoríase. 
 
Palvras-chave: desenho factorial Box-Behnken, Etanercept, hidrogel, metotrexato (MTX), 
nanopartículas sólidas lipídicas (SLN), terapia direcionada, transportadores lipídicos nanoes-
truturados (NLC) 
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Abstract 
 
 
 
 During the last decades, inorganic and colloidal carriers have been discovered for der-
mal/transdermal drug delivery. The successful implementation of these systems for drug 
delivery entirely depends on their ability to go through numerous anatomical barriers, sus-
tained release of their content and their stability in the nanometer siz.  
 Among these lipid colloidal delivery systems Solid Lipid Nanoparticles (SLN) emerged in 
the early nineties as an alternative and, current trials applying SLN consider them very 
promising in drug delivery. In fact, it is widely accepted that SLN combine the advantages 
and avoid the disadvantages of other colloidal carriers. Low drug loading and drug expulsion 
during storage period are taken as the disadvantage of solid lipid nanoparticles.  Nanostruc-
ture Lipid Carriers (NLC) have been developed to overcome the drug loading limitation of 
SLN, by decreasing the degree of the lipid matrix organization. NLC are based on a mixture 
of solid and liquid lipids that results in an imperfect matrix thus, in an increase of the drug 
loading. As liquid lipids exhibit higher solubility for drugs, NLC have a higher loading capaci-
ty than SLN, as well as an improved drug controlled release. Many administration routes are 
being investigated for lipid nanoparticles, including topical, oral and parenteral ones.  
Methotrexate (MTX) is a folate antagonist used in the clinics for the treatment of differ-
ent solid tumours and in the therapy of autoimmune and inflammatory diseases as rheuma-
toid arthritis and psoriasis. To overcome the drawbacks (e.g. hepatotoxicity, ulcerative coli-
tis, nephrotoxicity) associated with MTX administration colloidal delivery systems can be ap-
plied. The first aim of the present research was to develop a lipid based delivery system for 
MTX safe administration.  
A formulation design requires full knowledge of the relationship between the process pa-
rameters and the quality attributes. To reach an optimized formulation using traditional 
screening approach (one factor at a time) is difficult, inefficient and time consuming. A  
The statistical formulation design is a validated and useful approach to develop a formu-
lation with less experimentation and providing enough information on the relationship be-
tween independent and dependent variables. Few studies have optimized lipid nanoparticles 
using factorial design and is widely accepted that the ingredients have great influence on the 
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physicochemical properties. Here, the effect of the formulation composition in the optimiza-
tion of MTX-loaded NLC by means of a Box-Behnken factorial design is described. The formu-
lation was produced using the hot ultrasonication method, using Witepsol®E85 as the solid 
lipid and Mygliol®812 as liquid lipid, and their physicochemical properties (morphology, par-
ticle size, polydispersity, zeta potential, and entrapment efficiency), in vitro drug release 
studies and cytotoxicity were investigated. Optimized NLCs loaded with MTX exhibited 
spherical shape with 252-nm, a polydispersity of 0.06 ± 0.02, zeta potential of -14 mV and an 
entrapment efficiency of 87%. In vitro release studies revealed a fast initial release followed 
by a sustained release of MTX from the NLC up to 24-hours. The release kinetics of the opti-
mized NLC best fitted the Peppas-Korsmeyer model for physiological and inflammatory envi-
ronments and the Hixson-Crowell model skin simulation conditions. No toxicity was observed 
in fibroblasts. Thus, the optimized MTX-loaded NLC have the potential to be exploited as 
delivery system. 
 The second aim of this research was to design and characterize a targeted delivery sys-
tem for topical application in psoriasis. Besides delivery of MTX, NLC and SLN were function-
alized with Etanercept, a monoclonal antibody currently used in psoriasis biological therapy, 
to obtain a target therapy. These nanoformulations were incorporated into a hydrogel to 
eventually facilitate their penetration in a dermal barrier. The formulation was produced by 
the method described above, using cetyl palmitate as solid lipid and Miglyol 812 as liquid 
lipid, and were characterized in terms of: physico-chemical properties, in vitro drug release 
profile, in vitro cytotoxicity in keratinocytes (KC) and fibroblasts, skin permeation profile 
and rheological properties. All nanoformulations presented size closer to 400 nm, -30 mV, 
polydispersity index below 0.3 and high values of drug content. Furthermore, morphological 
investigations by TEM and Cryo-SEM showed that all nanoparticles exhibit a spherical shape 
and a smooth surface independently of their composition and were stable at least 6 weeks at 
room temperature. MTX release showed a fast initial phase followed by a sustained drug re-
lease. Furthermore, we produced a hydrogel (Carbopol
®
 934) enriched with empty LNs, MTX 
loaded LNs, F-LNs and MTX loaded F-LNs. Rheological tests showed that all the designed for-
mulations had a non-Newtonian, pseudoplastic, thixotropic behavior, suggesting that they 
are suitable for topical drug delivery with a small decrease of it consistency in 2 weeks. Skin 
permeation assays demonstrated that, mimicking physiological values and temperature, LNs 
loaded with MTX have good levels of MTX and protein penetration through pig ear skin. A 
small decrease of MTX permeation was observed when LNs were embedded in the hydrogel.  
 The main results obtained for both approaches of this work reveal that produced lipid 
colloidal carriers show interesting properties for delivering MTX. Present results demon-
strated that these systems could be a promising platform for inflammatory diseases, in par-
ticular for psoriasis topical therapy. 
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Chapter 1- Aims and Organization of dis-
sertation  
 
 
 
      This dissertation aims to improve methotrexate (MTX) administration in psoriasis (PSO) 
topical therapy. To achieve this goal specific objectives were defined: (1) to ascertain if 
Box-Behnken design approach is suitable to optimize the production of lipid nanoparticles 
containing MTX; (2) to develop a topical therapy through the design of an innovative hy-
drogel enriched with MTX loaded lipid nanoparticles; (3) to produce a combination therapy 
with currently used psoriatic drugs: Etanercept and MTX, eventually for a systemic or topi-
cal administration. 
      Since the beginning of the 1990s, lipid based nanoparticles have features that make 
them interesting for the pharmaceutical and cosmetic technology research. Lipid nanopar-
ticles as solid lipid nanoparticles (SLN) and their second generation, the nanostructured 
lipid carriers (NLC) have been investigated as carrier systems for many applications, and 
will be used in this work.  
 This dissertation is organized as follows: Aims and organization of dissertation, intro-
duction and state of art, materials and methodology, results and discussion and conclu-
sions including future work. In the introduction the skin histology and physiology are de-
scribed, as well as the different types of drug for skin as administration route; also PSO is 
exhaustively detailed through its epidemiology, clinical and histopathology features and, 
its pathogenesis and genetics basis as well the traditional treatment according to class of 
drugs and administration routes. A particular focus will be given to skin as administration 
route for PSO, with respect to the uses of lipid nanoparticles, novel therapeutic approach-
es for PSO in general and the features of lipid nanoparticles in particular were mentioned. 
After the methodology section where the theoretical principals and experimental details 
for each method are described, the results of this dissertation are detailed and discussed. 
 Within the results section two parts are described, at first the application of formula-
tion design approach to optimize the production of NLCs loaded with MTX, including their 
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physico-chemical properties and biological safety. The second part of the results section 
focus two therapeutic strategies for PSO: a topical therapy based on a hydrogel enriched 
with lipid nanoparticles and a targeted combined therapy using etanercept and MTX. The 
developed delivery systems were characterized and investigated with regard to physical 
(size, charge, morphology, storage stability), chemical (drug loading, in vitro drug release), 
biological (in vitro cytotoxicity and skin permeation profile) and rheological properties. All 
of the results and main conclusions obtained were exposed in next sections. 
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Chapter 2- Introduction and State of art 
 
 
 
2.1 Psoriasis 
 
2.1.1 Epidemiology of psoriasis 
 
      Originally, this disorder thought to be associated with abnormal differentiation and 
hyperproliferation of epidermal keratinocytes (KC), but now is known as one of the com-
monest immune-mediated disorders [1]–[3]. 
 Around 2-3% of the world’s population live with PSO and the prevalence appearing to 
be relatively highest in Scandinavian countries (8.5% in Norway), Northern Europe, Ameri-
can and Canadian populations (4.6 and 4.7%, respectively) [4]–[8]. The prevalence varies 
substantially between countries and appears to be relatively frequent in countries of high-
er latitude [9]. 
 Studies of monozygotic twins propose a 70% possibility of a twin developing PSO if the 
other twin has the disease. These findings suggest both a genetic predisposition and an 
environmental response in developing PSO [23–25]. Though, PSO can be transmitted genet-
ically it does not spread from one person to another by contact [14, 25, 26]. 
 PSO affects people of all ages but occurs most usually in the third decade of life (a 
peak between 15 and 30 years) and another peak between 50 and 60 years [20, 24, 27], 
[28]. Children are rarely affected [14, 25]. Psoriatic arthritis (PSA) is a chronic inflamma-
tory type of arthritis associated with PSO, usually seronegative for rheumatoid factor [24, 
29, 30]. Its pain, stiffness and swelling in and around the joints and the sites where ten-
dons and  ligaments attach to bone [17]. 
 
 
2.1.2 Clinical features of psoriasis 
 
 In early-onset of PSO, developing before the age of 40 years, genetic and environmen-
tal factors have a crucial role. The triggers include emotional stress, skin injury, systemic 
infections, among others [14, 17]. PSO can be an enormously disabling disease which could 
impact significantly on a patient’s quality of life (QoL) [4]. 
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 The common type of PSO is called PSO vulgaris or large plaque PSO and is caused by 
unsuitable activation of the cellular immune system [15, 22, 27, 31]. PSO is a 
papulosquamous disease with formation of  erythematous, inflamed and raised plaques 
that are well-demarcated in the region of normal skin [14, 15]. The plaques are red or 
salmon pink in colour, covered by grey or silvery-white, dry scales and could be thick and 
have few or more millimeters [15, 24]. Plaques are frequently dispersed symmetrically and 
take place in any part of the body (Figure 2.1) on the extensor aspects of elbows and 
knees; scalp, where they not often invade beyond the hairline, lumbosacral region, and 
umbilicus [15, 24].  
 
Figure 2.1 - Psoriasis vulgaris localizations. Adapted from [19], [20]. 
 
 PSO vulgaris to be associated  with phenotypically and genotypically distinct conditions, 
which might account for the variability of response to therapy, mainly with the T-cell tar-
geted biological agents [2]. 
 Occasionally PSO may involve the oral mucosa or the tongue and when that happens, 
the dorsal surface may have stridently gyrate red patches with a white -yellow border [11]. 
 In addition, diverse forms of PSO may be limited to a small or extensive area. Further, 
PSO may have a variable course exhibiting as chronic, stable plaques or can present acute-
ly, with a rapid progression and widespread [11]. 
 Regardless of advances in our understanding of the pathogenesis of PSO, there have 
been no large, representative, prospective and longitudinal studies about the natural his-
tory of the disease, mainly predictors of disease severity [15, 22]. 
 
 
2.1.3 Histopathology of psoriasis 
 
 The characteristic histological features can be traced to specific immunological re-
sponses and will be listed: 
 Hyperproliferation of basal KC gives rise to acanthosis, thickening of the epi-
dermis resulting from augmented numbers of acanthocytes (‘prickle cells’). This 
thickening occurs in ridges, with surrounding areas of thinning taked by elon-
gated dermal papillae, and elongation of the epidermal rate ridges 
(papillomatosis). Hyperproliferation is accompanied by incomplete differentia-
tion and maturation so that the cells are shed abnormally in large clumps. In 
addition, the loss of the granular layer (hypogranulosis) [20, 34]. 
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 The thickening of the epidermis and the connected silvery scale are due to 
premature KC maturation and succeeding incomplete cornification, which result 
in retention of nuclei inside the cells of the stratum corneum (SC) 
(parakeratosis) [7]. 
 Dilatation and elongation of capillaries occurs induced by angiogenic factors 
[such as vascular endothelial growth factor (VEGF)]. Auspitz sign is a typical 
finding in PSO and it is relates to the manifestation of small bleeding points fol-
lowing consecutive layers of scale from the surface of psoriatic papules or 
plaques. These reach the top of the dermal papillae and almost enter to the 
surface of the skin [20, 34, 35]. 
 Infiltration of the dermis and epidermis by neutrophils, lymphocytes, macro-
phages and dendritic antigen presenting cells (APCs). The neutrophils frequent-
ly form cumulations termed ‘microabscesses of Munro’ (in the SC) or 
‘micropustules of Kogoj’ (in the upper epidermis) [21]. 
 
 
2.1.4 Pathogenesis of psoriasis 
 
 An insight of the molecular mechanisms associated with pathogenesis of PSO gives cru-
cial importance to the interaction between acquired and innate immunity [23]. Both clini-
cal and fundamental investigation specify that the cellular innate and adaptive immuno-
logical responses, in particularly the activation of T cells, play a crucial role in the patho-
genesis of PSO [24]. 
 The activation of T-cells is necessary upon its binding with the APCs. This process is 
mediated through surface molecules used for adhesion, counting leukocyte function con-
nected with antigen lymphocyte function-associated (LFA)-1 and cluster of differentiation  
(CD2) on the T cells and, intercellular adhesion molecule (ICAM)-1, and LFA-3 on the APCs 
[25].  T-cell receptor is specific for T-cell acknowledge an antigen existing on the histo-
compatibility complex (MHC I or II) by the APC Figure 2.2. Activated T cells propagate and 
go in the circulation via trafficking through the interaction between LFA-1 and ICAM-1. 
 Then, extravasate via diapedesis through the endothelium at place of inflammation in 
the skin [26]. The activation of intracellular signal transduction pathways and production 
of cytokines/chemokines plays a vital position in reinforcing the inflammatory immune 
process as it transports lymphocytes to the site of inflammation and disrupt their prolifer-
ation [18]. 
 Antimicrobial peptides (AMPs) are a significant constituent of the innate immune sys-
tem and play a main role in the homeostasis of surface organs such as the skin. The over-
expression of AMPs is a feature of PSO and can be exposed as a sign of activation of the 
innate immune system [23].  
 The elevated production of VEGF by KC, activated T cells and endothelial cells is per-
suaded by cytokines such tumor growth factor-α (TGF-α), interferon (IFN-γ) and tumor ne-
crosis factor-α (TNF-α) and the neutrophils that are found in great number, increasing vas-
cular permeability [26]. 
 In the beginning of the disease, there are a significant quantity of macrophages, fol-
lowed by cells such monocytes, lymphocytes, granulocytes in epidermis, as illustrated on 
Figure 2.2 [37, 39]. Histological features leading to the development of clusters of cells 
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are composed by dendritic cells (DC) and CD4+ T cells in the dermis or CD8+ T in the epi-
dermis [37,40]. DCs generate cytokines TNF-α, IFN-γ and interleukin IL-23 (heterodimeric 
cytokine draw up of a single IL-23p19 subunit coupled with a common IL-12p40 subunit, 
which is shared with IL-12) and are able to establish inflammation and possibly stabilize 
the phenotype of T helper cells (Th-17). This may occur throughout mechanisms depend-
ent on the transcription factor STAT3, mediating Th17 terminal effector functions, IL-22 
motivate the development of specific subclasses of T cells (Th1, Th17, Th22) and pro-
inflammatory [20, 31, 36, 41, 42]. 
 
Figure 2.2 - Representation of psoriasis pathogenesis. Adapted from [29] 
 
IL-22 induces hyperproliferation of KC and both IL-17 and IL-22 persuade activation and 
to the production of AMPs that leads to activation of the immune system and plentiful cy-
tokines and inflammatory mediators persist in psoriatic skin lesions (e.g. IL 8/chemokine 
CXC ligand (CXCL)8, monocyte chemotactic protein (MCP)-1/chemokine CC ligand (CCL)2, 
CXCL1, CXCL2, and CXCL3, and CCL20)[31, 41, 43]. These chemokines attract leukocytes 
such as neutrophils, DCs, chemokine CC receptor (CCR)6+  and also CXCL9, CXCL10 and 
CXCL11. IFNγ is released throughout Th1 cells and a subset of Th17 cells and plays a vital 
role in the maintenance phase of PSO, additional activating myeloid DCs and amplifying 
response circuits [29]. 
 There are others cytokines (e.g. IL-22, IL-19, IL-20 and KC-derived IL-36) that induce 
epidermal proliferation [29]. Indeed, KC products influence immune activation and induce 
of new adhesion molecules for T cells [44, 45]. 
 An unregulated function of resident skin cells such as fibroblasts and endothelial cells 
may possibly also supply to the pathogenesis of PSO [32]. 
       Mutations in epidermal CARD14 (mCARD14) in familial PSO may amplify endogenous 
activation in response to a trigger, inducing abundant cytokine and chemokine production 
(such as IL-8, CCL20, and IL-36) [29].  
 
 
2.1.5 Clinical types of psoriasis 
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 The clinical phenotypes of PSO, illustrated on Figure 2.3, have been sorted based on a 
variety of features such as: age of onset, degree of skin involvement, morphologic pattern 
and predominant involvement of specific anatomic location of the body [34]. Following, 
are described the main diagnostic features of four clinical phenotypes: 
 
Type I - Plaque or vulgaris psoriasis 
 The plaque PSO is the most frequent form [1]. Patients have sharply well-delineated, 
round/oval or nummular (coin-sized), scaly and dry plaques (Figure 2.3 a,b). The lesions 
may at first begin as erythematous macules or papules, extend peripherally, in a fairly 
symmetrical distribution [34, 46]. The rupioid and ostraceous notions speak about to mor-
phological subtypes of plaque PSO meaning small plaques and ostraceous PSO refers to 
hyperkeratotic plaques with relatively concave centres [11]. 
 The quantity of scaling varies among patients and even at different sites and their re-
moval may expose tiny bleeding points (Auspitz sign) [34]. The lesions can emerge at any 
part of body but the majority sites are elbows and knees [24, 46].  
 
Figure 2.3- Images of types of psoriasis. A) small plaque psoriasis; B) large plaque psoriasis; C) 
guttate psoriasis; D) erythodermic psoriasis; E) pustular psoriasis. Adapted from [49, 50] 
 
Type II - Guttate psoriasis 
 Guttate PSO  Figure 2.3 c , from the Greek word gutta meaning a droplet [1]. It ap-
pears on as small diameter lesions of PSO and affects specially children and adolescents, 
under a streptococcal infection of the pharynx or tonsils or the upper respiratory infection 
[24, 46]. These are usually distributed in a centripetal away but can also involve the head 
and limbs. Sometimes lesions form on scalp, face and ears [24, 47]. 
 This type of PSO accounts for 2% of the overall cases of PSO. In children, an acute epi-
sode of guttate PSO is usually self-limiting but in adults, these events may development to 
chronic plaque disease. One small study exposed that 33% of patients with acute guttate 
PSO perhaps developed chronic plaque disease. In other words, patients have a significant-
ly higher risk for developing plaque PSO in the future. As a result, this form co-exist with 
other forms of PSO [24, 46, 47]. 
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III - Erythroderma 
 This type involve almost the skin with active PSO [24, 46] as shown on  Fugure 2.3 d. 
Firstly, chronic plaque PSO may gradually progress as plaques resulting in an exacerbation 
of instability of this plaques [14, 46]. Secondly, erythroderma may be a manifestation of a 
withdrawal of a systemic medication [34]. Erythroderma may harm the thermoregulatory 
capacity of the skin, metabolic changes including hypoalbuminaemia, high output cardiac 
failure and anaemia due to loss of iron, vitamin B12, and folate [11].   
 
IV- Pustular psoriasis 
 This form is rare and this events may occur randomly on any part of the body when the 
collections of neutrophils are great enough to be evident clinically, it is termed ‘pustular 
PSO’, as illustrated on Figure 2.3 e [46, 48]. There are two main forms: generalized 
pustular PSO (Vom Zumbusch) and localized pustular PSO. Both types lead to red, painful 
and inflamed skin with a multiple pustules in a erythematous base [24, 46]. Generalized 
pustular PSO (von Zumbusch) is rare and represents active and unstable disease [11]. Pa-
tients with this type frequently need to be admitted to the hospital for management and 
close monitoring. Localized pustular PSO that admits acrodermatitis continua of Hallopeau 
is characterized by eruption of the fingers and toes and, palmoplantar pustulosis manifests 
as pustules on palms and soles. Plaque formation is not characteristically seen in this type 
[34]. 
 
 
Phenotypes of psoriasis in accordance with involvement of anatomical region  
 PSO can also be classified according to the affected anatomical sites, as illlustrated in 
Figure 2.4, and can be classified in five types: 
 Palmoplantar pustulosis: is presented as thick and yellow pustules on a back-
ground of erythema and scaling have an effect on the palms and/or soles, Fig-
ure 2.4 a[24, 46] . 
 Psoriatic nail disease: occurs approximately in 15% to 53% of Pso patients and, 
up to 10% announce with only nail manifestations with no other manifestations 
[49, 50]. Fingernails are more usually affected than toenails (Figure 2.4 b). The 
frequent finding are small pits in the nail plate, onycholysis, oil spots (orange-
yellow areas), hyperkeratosis [46, 49], 50]. In addition, the site around nail 
plate may become, thickened, dystrophic, and yellowish-brown nail discolora-
tion[46, 50] . 
 Flexural (inverse) psoriasis: affects 2% to 7% of patients with PSO and has re-
percussions on flexures, particularly inframammary, genitalia, and axillary (Fig-
ure 2.4 c). In other words, there are intertriginous involvement whilst plaque 
PSO affects trunk and limbs [46, 49, 50]. In general, this type of lesions are de-
prived of scale and appear as smooth, red, shiny, well demarcated plaques oc-
casionally confused with candidal, intertrigo, and dermatophyte infections.  
 Scalp psoriasis:  is one of  the most frequent  site  with manifestation of plaque 
PSO (Figure 2.4 d) and may be present in up to 79% of patients with PSO [49, 
50]. The lesions are typically sharply demarcated, asymmetrical and sometimes 
advanced beyond hair border on the face, neck or auricular regions [38]. It is 
a b 
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linked with seborrheic dermatitis and is difficult to distinguish from scalp PSO 
[38]. 
 Genital psoriasis: occur in all age groups from infants to the elderly. Nearly 
one-third of patients with PSO suffer from genital PSO [34].  
 
Figure 2.4 - Images of psoriasis classified in accordance with involvement of anatomical region. A) 
palmoplantar;  B) psoriatic nail disease; C) flexural (inverse) psoriasis; D) scalp psoriasis. Adapted 
from [51, [2]   
 
 
2.2 Treatment and drugs applied in psoriasis 
 
 Most patients are mildly affected by PSO and can be treated effectively with topical 
medication, but 10–20% of patients have moderate-to-severe disease and need a systemic 
treatment or phototherapy [16, 53]. Also, in patients with moderate-to-severe PSO, com-
bination therapy is frequently [42]. 
 The selection of an adequate therapy depends on several factors: extent of body sur-
face area and severity, patient predilection, practitioner experience, characterization of 
PSO phenotype, genotype, co-morbidities and the risk of adverse events from therapies 
[17, 45, 53]. 
 
 
2.2.1 Topical therapies 
 
 First-line management of adult mild-to-moderate PSO is with topical treatment, listed 
on Table 2.1[17, 40, 55, 56].This kind of treatment have a favorable risk/benefit profile 
when used and is very efficient against itching [23]. Tar has been used on PSO for a long 
time. Coal tar is the mainly form used and is a product obtained of coal distillation con-
taining more than 10,000 compounds. Its effect is probably throughout DNA suppression 
[45]. The accurate effectiveness of anthralin is complicated to establish, but it is known to 
inhibit human monocytes resulting in a decrease production of cytokines [46]. Furthermore, 
anthralin is often used in combination with phototherapy (ultraviolet B) [45].  Retinoids 
have proved to be useful in modulating KC proliferation and in reducing inflammation. 
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These compounds have been used as oral treatment for PSO for a long time, but recent 
innovations lead to development of a topical formulation based in tazarotene [47]. This 
agent is thought to perform at the gene level, via retinoic acid receptors, which mediate 
KC proliferation and differentiation and, their use is likely to increase over time due to 
their capability to induce long remission periods [45]. Calcineurin inhibitors have a role in 
the management of PSO associated with the activation of T-lymphocytes binding to intra-
cellular proteins and blocking the effect of calcineurin. This leads to a reduced production 
of interleukin-2 and reduced proliferation of T-cells [60, 61]. Topical corticosteroids 
(steroids) form the base of therapy for PSO due to their anti-inflammatory (dermal) effects, 
with high potency steroids being the most efficacious [52, 62]. They stimulate or inhibit of 
genes involved in inflammatory pathways, including inhibition of cytokine production and 
reduction in inflammatory mediators [51]. There is a scale, ranging from class 1 (highest 
potency) to class 7 with efficacy rates ranging from 41- 92% [51, 55]. Topical corticoids 
should not be used over extended periods (more than 6 weeks constantly) without disrup-
tion due to it typical corticoid side effects such local cutaneous like skin atrophy [36, 51]. 
Vitamin D analogues (calcipotriol, calcitriol, tacalcitol) have come into broad use recently. 
They restrain KC growth, support their differentiation, and reduce inflammation in psoriat-
ic lesions via vitamin D receptors on  KC and T lymphocytes [45]. These, too, have a posi-
tive risk/benefit profile. Although they are a little less efficient than elevated potency 
corticosteroids [23]. 
 In resume, corticosteroids stay essential to PSO treatment, but vitamin D derivatives 
are important to be used either in conjunction with steroids or alone, due to their anti-
proliferative (epidermal) effects [56, 57]. The combination of medications is maybe the 
most promising topical treatment with amplified efficacy and less side effects [57, 63]. 
 The principle of blending two drugs may be prosperous, but not all combinations offer 
positive or synergistic effects [48]. 
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Table 2.1 - Current treatment options for psoriasis 
Class 
Examples of 
agents 
Mode of action Side effects Refs 
Vitamin D 
analogue 
Calcipotriol 
Reduce production of 
pro-inflammatory cyto-
kines 
Pruritus, burning, 
sharp pain, ery-
thema 
[60, 
[63] 
Calcitriol - 
Anorexia, head-
ache, sweting, 
polyuria and 
hypercalmia 
[50] 
Keratolytic 
agents 
Salicylic acid 
Reduce the intercellu-
lar bonding of 
corneocytes and the SC 
pH 
Skin irritation, 
stinging in the 
applied area, 
headache, fast 
breading, ringing 
in ears 
[52] 
Urea 
Dissolves intercellular 
matrix 
Severe skin irrita-
tion, mild sting-
ing, itching and 
skin rash 
[55, 
[65] 
Omega 3 fatty 
acid 
Inhibition of lympho-
proliferation and T-
cells immune respons-
es; prevents produc-
tion of pro-
inflammatory cytokines 
Rash, itching, 
wheezing, diffi-
cult breading or 
swallowing 
[54] 
Calcineurin 
inhibitors 
Tacrolimus 
Inhibition of T-cell 
activation by the 
calcineurin pathway 
and inhibition of the 
release of numerous 
inflammatory cytokines 
Burning or itching 
sensation, flu-like 
symptoms and 
headache 
[48] 
Pimecrolimus 
Similar to tracolimus 
but more selective, 
with no effect on den-
dritic (Langerhans) 
cells 
Burning, soreness 
of treated skin, 
swelling of lips, 
face, tongue and 
throat. 
[55] 
Hydroxyanthrone Dithranol 
interferes with 
mithocondrial supply of 
energy to the cell and 
DNA replication 
Skin irritation, 
burning, itching, 
bron discoloration 
of diseased skin 
[46] 
Coal Coal tars 
Suppression of hyper-
plastic skin 
Staining, irrita-
tion and carcino-
genic risk 
[53] 
Retinoids Tazarotene 
Decrease of inflamma-
tion in the epidermis 
and dermis 
Pruritus, burning 
sensation, ery-
thema, irritation 
and dried skin. 
[59, 
60] 
 Acitretin 
Modulates mitotic ac-
tivity and differentia-
tion of KC 
Vitamin A toxicity 
(xerosis, alopecia, 
bleeds, skin fra-
gility) 
[12, 
68] 
Corticosteroids 
bethamethaso
ne 
diproprionate 
Control cellular pro-
teins leading to a 
broad range of anti-
inflammatory, immu-
nosuppressant and vas-
oconstriction actions. 
Skin infections, 
perioral dermati-
tis, skin atrophy 
and 
hypertrichosis. 
[52, 
55] 
fluocinolone 
acetonide 
Skin thinning, 
striae, skin atro-
[58] 
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Adapted from  [8, 12, 51, 52, 55, 57–60, 62, 63, 66–72]. 
 
 
2.2.2 Systemic therapy 
 
      Systemic therapy, listed on Table 2.2, should be considered when topical treatments 
fail in a clinical benefit and in patients with widespread cutaneous disease. In other words 
patients with moderate-to-severe PSO and/or related PSA [36, 40, 73]. This therapy can be 
complex compared with topical therapy by severe side-effects and their use demands a 
precise monitoring of patients [28]. So far, the systemic agents available for the treatment 
of PSO includes retinoids (acitretin), cyclosporine A (CyA) and MTX [57]. 
 Oral retinoids such acitretin are a group of natural and synthetic derivatives of vita-
min A, and have been advanced for the treatment of PSO since the early 1980s. Acitretin 
due to low efficacy and frequent side effects, is presently given almost exclusively in asso-
ciation with UV therapy, but this monotherapy with this drug can be efficient against 
pustular PSO [23]. Unpleasant reactions to retinoid such as teratogenicity, mucocutaneous 
effects and lipid changes have received much attention. Another side-effect interrelated 
to retinoid is skeletal toxicity [57]. Topical management of acitretin help to control the 
multiplication of cells, including the speed at which skin cells will grow and may decrease 
the risk of systemic toxicity as growing local bioavailability in the skin [64]. 
 CyA is an oral calcineurin inhibitor accepted for the treatment of plaque PSO since 
early 1990s. It suppresses the immune system and stops the activity of certain immune 
cells [65]. It is tremendously useful and thus appropriate for induction therapy, though not 
for long-term maintenance therapy due to the risk of irreparable renal crash and also be-
cause of the eminent risk of skin cancer in patients who have before undergone photo-
therapy [42], [65]. CyA is normally used as a rescue drug or binding agent [66]. 
  
 
phy, itching, irri-
tation, purpura 
and 
hypertrichosis. 
prednicarbate 
Down regulation of IL-
in KC. 
Burning sensation, 
itching, rash, 
reddening of skin 
and folliculitis. 
[60, 
69] 
flurandrenoline 
Act on phospholipase 
A2 inhibitory proteins. 
It will inhibit 
arachidonic acid and 
regulate biosynthesis 
of inflammation. 
Polyuria, 
polyphasia, 
weight gain, gas-
tro-intestinal ul-
ceration, pancre-
atitis, osteoporo-
sis and hypergly-
cemia. 
 
[60] 
bethamethaso
ne valerate 
Irritation, dry-
ness, folliculitis, 
striae, 
hypertrichosis, 
acneiform erup-
tions and perioral 
dermatitis. 
[52, 
55] 
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Table 2. 2- Available systemic treatment options for psoriasis (Adapted from [47-61]) 
 
MTX, the oldest systemic therapy for PSO, still remains one of the most successful 
treatments for PSO and PSA. MTX is a folate antagonist that competitively bind to 
dihydrofolatereductase hampering cell growth and arresting cell cycle in G1/S phases and 
has been used in the clinics since the fifteens for the treatment of different solid tumours 
(e.g. osteosarcoma, lung and breast cancer) [67] and in the therapy of autoimmune and 
inflammatory diseases as rheumatoid arthritis (RA) and PSO [12, 13]. It acts by suppressing 
the immune system and thereby stopping the inflammatory response that can direct to 
PSO and psoriatic flares [77–79]. MTX is one of the most effective therapeutic agents with 
a triple mode of action: it is anti-inflammatory, reduces cell proliferation and it is immu-
nosuppressant. It is accessible to treat a variety of malignancies, such as osteosarcoma, 
non-Hodgkin’s lymphoma, lymphocytic leukemia, choriocarcinoma, and head, neck, and 
breast cancers. MTX is also used against non-neoplastic conditions such as severe PSO and 
autoimmune diseases such RA [13, 79, 80]. It has some short-term side effects including 
bone marrow toxicity, nausea, aphthous stomatitis, and development of megaloblastic 
anaemia. Liver toxicity is the main limiting factor of MTX treatment in PSO. The incidence 
 
Class 
 
Examples of 
agents 
 
Mode of action 
 
Side effects 
 
Refs 
Non-
biologics 
Cyclosporine 
(CyA) 
Inhibits activity of phos-
phatase of calcium-
calmodulin-calcineurin 
complex and promotes 
translocation of NFAT. 
Renal and liver fail-
ure, hypertension, 
nausea, vomiting, 
diarrhea, 
hypertrichosis and 
tremor. 
[47, 
48] 
MTX Folic acid antagonist that 
causes competitive inhibi-
tion of the enzyme 
dihydrofolate reductase. 
Liver fibrosis/ cirrho-
sis, bone marrow 
depression, renal 
damage, necrosis of 
soft tissue and bone. 
[49, 
50] 
Biologics 
Efalizumab Prevents interaction of T-
cell with endothelial cells 
and KC, movement of T-
cell from the blood vessels 
into the tissue and activa-
tion of T-cell. 
Flu-like reactions, 
leukocytosis, lym-
phocytosis and ar-
thralgia. 
[51, 
52] 
Alefacept Interact with CD2 on T-
cells and interferes with 
T-cell activation. 
Decrease in CD4+ T 
cells, itching, nau-
sea, muscle aches 
and allergies risk of 
infections. 
[53,
54] 
Infliximab Bind both to soluble and 
membrane-bound TNF-α 
Infusion reactions, 
severe infections and 
progression of heart 
failure. 
[55,
56] 
Etanercept  Interacts with soluble TNF-
α and blocks the cascade 
of inflammation stimulat-
ed by TNF-α. 
Infections, local re-
actions, sore throat, 
headache, hair loss, 
and rash. 
[57] 
Adalimumab Binds with high affinity to 
soluble and membrane-
bound TNF-α.  
Locally: swelling, 
redness, pain and 
itching and shortness 
of breath. 
[58,
59] 
Ustekinumab Bind p40 subunit of IL-12 
and IL-23 and prevents 
their interaction with the 
corresponding receptors. 
pharmacokinetics are 
strongly affected by 
body weight 
[60,
61] 
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of liver toxicity including liver fibrosis varies considerably depending on underlying risk 
factors [77, 80]. 
 
2.2.3 Biologic therapy in systemic therapy 
 
 A major expansion of the therapeutic efficiency against PSO has arrive with the ap-
proval of a number of "biologics" which have a good benefit-risk profile overall and are also 
successful in patients who cannot be treated satisfactorily with the systemic therapies 
available till now [73]. As of 2010, seven biologic drugs have obtained a food and drug ad-
ministration (FDA) approval for the treatment of PSO and/or PSA [66]. Biologics are, by 
definition, genetically or biotechnologically generated products of living cells. They can be 
cytokines, fusion proteins composed of surface molecules, T cells or monoclonal antibodies 
towards the CD11 a subunit of LFA-1 (eg. efalizumab), or the p40 subunit of IL-12 ⁄IL-23 
(eg. ustekinumab) or to TNF-α (eg. adalimamub, infliximab and etanercept). Monoclonal 
antibodies therapy will compensate the disequilibrium of the inadequately regulated im-
mune system, leading to improvement of the clinical manifestations and block specific 
molecular steps in the inflammatory cascade, thereby reducing activation and prolifera-
tion of  KC [36, 81–83].  
 TNF-α inhibitors differ in mechanism of action and structure [40,81–84]. Adalimumab 
is a human monoclonal antibody to TNF-α and functions in the same way as infliximab. In-
fliximab is a chimeric mouse-human monoclonal antibody to TNF-α that can bind both sol-
uble and membrane-bound TNF-α and successfully neutralize its activity [81, 82, 84]. 
Etanercept is a neutralizing recombinant soluble TNF-α receptor (human p75 TNF-receptor 
Fc fusion protein) and binds free TNF-α and lymphotoxin [40, 81, 83, 84]. 
 The effectiveness of etanercept in the treatment of PSO is comparable to that of the 
antibodies [40]. Golimumab, a new anti-(human TNF-α) antibody, has already been used 
with success in patients with PSO [40]. The most common side effects included upper res-
piratory infections, nasopharyngitis, and headache [83, 85]. Certolizumab, a humanized 
antibody, TNF-α blocker that is effective in other immune-mediated diseases, such RA [40, 
83]. Due to the considerable cost and risks related with TNF- α inhibitor therapy, these 
agents can only be used in patients with general skin disease or in patients with inade-
quate skin disease unresponsive to topical and/or targeted phototherapy [40, 82]. Despite 
this, it is likely that the therapeutic profit of TNF-α inhibitors is due not only to the ob-
struction of the soluble cytokine, but also to the neutralization of membrane bound TNF-α 
[40]. Recently, there are antibodies (anti-TNF-α) that may also act on the central IL-23–
Th17 axis [40]. 
 Efalizumab, is an antibody against the cell-surface adhesion molecule LFA-1 present 
on the T-cell surface, and inhibits the migration of inflammatory cells into the skin. It is 
effective only against PSO vulgaris. Successful treatment is accomplished after six months 
in about 40% of patients, but some patients can also profit from long-term therapy [36, 40]. 
Despite this, in 2009 it has been obliterated from the market due to progressive multifocal 
leukoencephalopathy [86, 87]. 
 Alefacept is a fully human LFA3–IgG1 fusion protein that targets CD2 and inhibits T-cell 
activation and proliferation. Alefacept also promotes apoptosis of memory T-cells [40, 83]. 
It was the first FDA sanctioned biologic agent for the treatment of PSO [83]. 
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 Ustekinumab, a IL-12/23 inhibitor, is a human monoclonal antibody towards the p40 
subunit, which is shared by both IL-12 and IL-23 cytok¬ines [82]. Furthermore, treatment 
was effective for at least 1 year while ustekinumab was administered every 12 weeks [40]. 
 Briakinumab (ABT-874), human monoclonal antibody against the p40 subunit of IL-12 , 
has not received FDA approval as of yet, but has been studied in one clinical trial [40], 
[83]. 
 Biological agents are listed on Table 2.2 are costly and demonstrate immunosuppres-
sant activity, and are presently indicated for patients powerless to benefit from first- and 
second-line modalities [82, 83]. 
 
2.2.4 Phototherapy 
 
 For moderate-severe PSO or no respond to topical treatment alone, the application of 
ultraviolet light (UV) is suitable for inducing a remission but not for maintenance therapy, 
because its extended use is related with an elevated risk of skin cancer [12, 85]. UV radia-
tion is broadly classified into three major spectrum ranges: UVA (320-400 nm), UVB (280-
320 nm), and UVC (280-100 nm) [77]. At present, the most commonly used type of photo-
therapy is with the narrow-spectrum UV-B therapy. The application of narrow band (NB)-
UVB has been possible on a widespread basis [17, 36].  
  
 
Table 2.3- Phototerapy used in systemic treatment (Adapted from [7], [54], [71], [85])  
Photo-
therapy 
Advantages Disadvantages Refs 
 
 
PUVA 
 Thick psoriatic plaques 
and nail disease 
 Involvement of palms 
and soles since 
 Failure to responds to 
UVB phototherapy 
 
 Skin cancer risk occurs 
after prolonged photo-
therapy with PUVA 
 Patient inconvenience 
 Higher running costs 
 Personal or family histo-
ry of melanoma is an 
absolute contraindica-
tion 
[12, 71, 
85] 
 
 
 
NB-UVB 
 Less risk than PUVA 
 Rapid and easy clear-
ance on exposure to 
sunlight 
 effective, safe 
 Young age 
 Contemplates/reports 
pregnancy or lacta-
tion. 
 
 
 Daily treatment is not 
better 
 Personal or family histo-
ry of melanoma is a rel-
ative contraindication 
to UVB 
 
 
The application of PUVA: UVA radiation after the administration of a photosensitizer 
(psoralen) by the oral route or as a cream is highly effective although is difficult to deliver 
[23]. The efficacy of PUVA therapy in PSO and some other diseases has evidently been rec-
ognized, both as a clearance and as a maintenance treatment and, it can be improved in 
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combination with other treatments such as CyA plus PUVA and retinoid plus PUVA [12, 85]. 
Also, a combination of PUVA and MTX can decrease the duration of treatment, yet main-
tains its efficacy [77]. 
The advantages and disadvantages of phototherapy are described in Table 2.3. The ap-
plication of systemic treatment and phototherapy is limited to treating severe PSO due to 
the carcinogenicity and their toxicity [54, 85]. 
The mode of action of each treatment applicable in phototherapy are shown in Table 
2.4. Taking into account some factors such as relative efficacy, costs, availability, and side 
effects, phototherapy in general, and the NB-UV therapy, seems to suggest the best thera-
peutic option for patients affected with moderate to severe PSO [77]. 
 
Table 2.4 - Current treatment options for psoriasis phototherapy. 
Agent Mode of action Refs 
Ultraviolet B (UV-B) 
Interaction between UV-B and DNA, gener-
ating pyrimidine dimers result in the inhibi-
tion of DNA synthesis. Reduce proliferation 
of lymphocytes and KC. 
[12,85] 
UV-A plus psoralen 
(PUVA) 
Upon UV-A activation psoralen combine with 
DNA leading to the inhibition of DNA synthe-
sis. Prevents cell hyperproliferation. 
[12, 71, 85] 
Methoxsalen 
UV radiation activates methoxsalen to bind 
DNA inhibiting the DNA synthesis. 
[78] 
 
 
2.3 Skin as barrier and administration route 
 
2.3.1 Histology of skin 
 
      Skin plays a vital role in maintaining homeostasis, defending against the invasion of 
microorganisms and providing protection from environmental attacks such as heat, chemi-
cals and toxins [79]. The skin is the largest and the most versatile organ of our body mak-
ing up 16% of body weight, with a surface area of 1.8 m2  and direct contact with external 
environment [80]. The skin  consists of three different layers: epidermis, dermis and hy-
podermis/subcutis as represented on figure 2.5 [89, 90]. Usually, epidermis and dermis 
are considered more important from a penetration perspective [88, 89].  
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 The epidermis is the outer layer, nonvascular and made of stratified squamous keratin-
ized epithelium which synthesis the protein keratin [81]. The separate layers of the epi-
dermis are formed by the differing stages of keratin maturation.  These layers are or-
dered in five different strata (stratum basale or germinative (in contact with dermis), 
stratum spinosum or princkle cell layer, stratum granulosum or granular cell layer, stra-
tum lucidum or horny layer and stratum corneum  in contact with the external environ-
ment) as represented on Figure 2.6. So, epidermis is histologically classified as a stratified 
epithelial layer [88, 90]. 
Figure 2.5 - Schematic representation of normal skin structure. 
 
 SC, the outermost portion of the epidermis is the main penetration barrier that pro-
tects the body from extreme water loss and damage due to toxic agents and microorgan-
isms from the environment and which cells are embedded in highly ordered lipid layers 
[89–91]. SC is a lipophilic layer and contains ≈ 13% of water and it hydration is vital to keep 
away from mechanical collapse.  Regulation is essential and guarantees preservation of SC 
enzyme activities [88,90, 92]. 
 There are four categories of intercorneocyte lipids namely cholesterol and its deriva-
tives, ceramides, free fatty acids and triglycerides [85]. Skin may also enclose aqueous 
pores that supply to the transdermal route of skin absorption [88, 89]. The barrier function 
provided of SC layer that is composed of corneocytes and intercellular lamellar lipid bi-
layers [86]. Under the epidermis is the vascular dermis, described by dense irregular con-
nective tissue and responsible for the strength and flexibility of the skin. It contains nerves 
endings, sweat glands, hair follicles and blood vessels and its accountable to carry nutri-
ents and oxygen to the epidermis, and as well clear the dermis from cell metabolic prod-
ucts and penetrated foreign agents [89, 90]. 
Figure 2.6 - Schematic representation of the stratum corneum structure. 
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 Underneath the dermis is the hypodermis or subcutis (fat) layer of connective tissue 
composed of loose textured, white, fibrous connective tissue in which fat and elastic fi-
bers are combined, that include two layers separated by a superficial fascia: the areolar 
layer, composed with large adipocytes arranged vertically and closest to the dermis and, 
the lamellar layer, a deeper layer, where the cells are smaller and arranged horizontally 
and the blood vessels are larger [87]. 
 The histology of skin is analogous in dissimilar regions of the body, except in the thick-
ness of the epidermis. Also present in the skin are sebaceous glands, sweat glands and hair 
follicles, closer to the connective tissue [88, 89]. It was not until 1960s–1970s that the sci-
entists reached the accord that: 
 SC is one of the most rate-limiting barrier against percutaneous drug penetra-
tion; 
 Particular content, composition, and structure of the SC lipids hold selectively 
and efficiently the penetration of chemicals [86]. 
 
 
2.3.2 Skin for drug delivery 
 
 Drug delivery through skin can be separated into topical delivery, transdermal delivery 
and subcutaneous injection represented in  Table 2.5 [79]. Skin is recognized as an attrac-
tive site for systemic drug delivery due to its large surface area, access convenience, and 
possibility of avoiding first pass metabolism in gastrointestinal tract and the liver [79]. The 
permeation barrier properties offered by human skin remains challenging as delivery 
routes for drugs and other compounds into the skin strata (topical delivery) and/or to the 
systemic exposure (transdermal delivery) [94, 96]. 
 
 Topical delivery is mainly used for achieving local effect and several examples exist of 
its utility in the critically ill [79]. A drug can be directly applied to the skin for treatment 
of several dermatological diseases through several formulations such as gels, lotions, 
creams, foams, and ointments. Is can also be used for local anesthesia, local infection 
management and photodynamic therapy. These topically delivered drugs should reach the 
viable epidermis or dermis to take effect [79]. For optimum topical delivery of drugs into 
the skin, it is necessary that the carrier releases the encapsulated drug in the skin or mu-
cous membrane, which can be additionally absorbed through the skin layers and through 
sub skin structures that are implicated in disease [87]. 
 Transdermal drug delivery aims to deliver drugs through the skin to achieve systemic 
effect [89]. Offers an attractive non-invasive alternative and could be achieved through 
this route, possibly decreasing drug side effects and improving efficacy. Other advantages 
of this route drug delivery include ease of drug application and therapy cessation. Further, 
greater duration of action is seen for drugs with a short elimination half-life given 
transdermally [87, 97]. 
 Subcutaneous drugs injected into the fatty subcutaneous tissue pass the epidermal 
and dermal layers of the skin and achieve the systemic circulation through capillaries or 
the lymphatic system depending on the drug molecular weight. Absorption of various drugs 
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through this way can be affected by formulation properties such injection volume, local 
degradation, viscosity and pH, formulation excipients and cellular uptake [79]. Theoreti-
cally, in this way a drug is applied in a moderately high dosage to the inside of a patch for 
an extensive period of time. Through a diffusion process, the drug go into the bloodstream 
directly through the skin [90]. 
 
Table 2.5 - Skin administration routes (topical, transdermal and subcutaneous) – formulation and 
applications (Adapted from [79]) 
 Topical Transdermal Subcutaneous 
Skin layer 
 
Epidermis or dermis 
 
Viable epidermis or 
dermis 
 
Subcutis (hypo-
dermis) 
Delivery 
mode 
Local Systemic Systemic 
Formulation 
Gels, lotions, creams, 
foams, and ointments 
Patches, gels, me-
tered dose spray, and 
ointment 
Solution 
Medication 
 
Treatment of skin dis-
ease 
Local anaesthesia 
Management of local 
infection 
Photodynamic therapy 
Analgesia; smoking 
cessation; cardiovas-
cular disease; 
Hormone replacement 
therapy 
 
Growth hor-
mones 
Insulin 
Epinephrine 
Limitation 
Local effects Skin permeability Limited injec-
tion volume 
 
 Compared to the other administration routes such as oral or intravenous, these deliv-
ery approaches, topical and transdermal, have the exceptional advantages namely [86]: 
 for dermatological diseases, topical drug deliveries approaches directly deliver 
therapeutic agents into place of the diseased cells;  
 lesser amounts of drugs are required to produce a therapeutic effect; 
 plasma level peaking of drugs will be avoid;  
 augment bioavailability since it avoids the hepatic first-pass metabolism;  
 greatly improved patient compliance by eliminating recurrent dosing. 
 
 The micro and macromolecules can enter into the skin through three distinct pathways, 
as represented on Figure 2.7 :[94, 95] 
 intercellular pathway, which is through the lipid matrix occupying the intercel-
lular spaces of the KC; 
 transcellular pathway, which is through the KC cells, 
 transappendageal pathway, which is across hair follicles, sebaceous glands and 
sweat glands. 
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Figure 2.7 - Schematic representation of different entry pathways for molecules into the skin. 
 
 Thus, by limiting the analysis of potential penetration through the skin anatomical fea-
tures, in healthy skin, only those agents lesser than 5–7 nm or 36 nm can respectively go 
through SC through intercellular route or aqueous pores, while larger ones (10,000–210,000 
nm) could enter skin through the transfollicular route [80]. 
 
 
2.3.3 Novel therapeutic approaches  
 
 Presently, it has become clear that the development of new drug alone is not always 
sufficient to ensure progress and success in new therapies, since the major reasons for the 
failure of drugs stay behind poor drug solubility, insufficient drug concentration related to 
reduced absorption, rapid metabolism and removal, drug distribution and allocation to 
other tissues, high drug toxicity, and high fluctuation of plasma level due to unpredictable 
bioavailability [1, 97, 99, 100]. 
 Treatment of PSO still remains a challenging task in spite of several therapeutic 
agents available due to absence of an ideal drug molecule. The main drawbacks are asso-
ciated with side effects caused by an inappropriate drug location that could be overcome 
with an efficient carrier for delivery of anti-psoriatic drugs, and lack of a suitable ani-
mal model mimicking histological and immunophenotypic characteristics of PSO [93]. For 
these reasons, it has become necessary to find new solutions as novel drug carriers. Colloi-
dal drug carriers can be generally classified on the basis of its components into Lipid 
based colloidal carriers and Polymeric colloidal carriers are represented on Figure 2.8. 
 
Figure 2. 8 - Classification of colloidal drug carriers. ( Adapted from [94]) 
 
 
 41 
 
 
2.3.3.1 Drug carriers for topical delivery 
 
 In case of dermatological diseases such as PSO whose triggers are situated beneath the 
skin, it is preferable to manage drugs topically rather than systemically due to more effi-
cient direct action with improvement of the local access for optimum amount of drug. 
 Topical administration also reduces the systemic burden and toxic effects of the drugs 
and it is considered the first-line of treatment currently used in moderate PSO as it is con-
sidered safe and well accepted by the patients with rates around (75-80%) [101, 103].  
 During the last decades, inorganic and colloidal particles such as nanocapsules, 
nanospheres, NLCs, among others, have been discovered for dermal/ transdermal drug 
delivery. The successful implementation of these systems for drug delivery entirely de-
pends on their ability to go through numerous anatomical barriers, sustained release of 
their content and their stability in the nanometer size [1, 88]. Various particulate lipid 
based colloidal carriers have also found application in anti-psoriatic drug delivery, in par-
ticular SLN and NLC [93]. 
 SLNs are the newest generation of lipid nanoparticles and are attracting attention as 
novel colloidal drug carriers for topical use. This kind of nanoparticles combine such ad-
vantages as sustained release of their content, insignificant skin irritation, organic solvent-
free preparation process and protection of active compounds [104, 105]. NLCs are a se-
cond generation of SLNs, and have been used in topical drug formulations and cosmetic 
products. Their diminutive size ensures close contact to the SC and their composition pro-
vides selective drug delivery to skin layers [64]. They are formed by integrating solid lipids 
with spatially incompatible lipids leading to a lipid matrix with a particular structure with 
several imperfections, as represented on Figure 2.9. These imperfections are caused by a 
blend of a liquid and solid lipids, providing more space for drug accommodation [1, 106]. 
 NLCs have the potential to adjust the drug release over an extended period with a re-
duced rate of systemic absorption. The lipid film formation above the skin and the suc-
ceeding occlusion effect was described for lipid nanoparticles with reduction of 
transepidermal water loss caused by this effect, leads to an augment in skin hydration af-
ter dermal application of SLNs or NLCs [74, 106, 107]. NLCs systems are a promising carrier 
for the topical delivery of antipsoriatic drugs as revealed by improved skin permeation and 
irritation, small and narrow size distribution, better bioavailability and the compatibility 
of the drugs [1, 106, 107].  
 
Figure 2.9 - Schematic representation of NLC and SLN structures. 
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2.3.3.2 Therapeutic agents review in the treatment of psoriasis 
 
  Lipid based carriers have attracted increasing scientific during the last few years as 
an alternative to polymeric nanoparticles and to overcome drawbacks associated with con-
trolled release, stability, biodegradability and economical costs. Table 2.6 describes some 
applications of vesicular lipid based carriers in treatment of PSO. 
 
 
Table 2.6 - List of lipid-based vesicular carriers for psoriasis topical therapy 
Carrier Drug Composition 
Size 
(nm) 
Skin penetra-
tion tests 
Refs 
L
ip
o
so
m
e
s 
tacrolimus DPPC:DLPC 77-88 
In vitro porcine 
skin 
[100] 
MTX 
Hydrogenated 
soya PC/  egg 
PC/ cholester-
ol/ menthol 
 
In vitro rat skin; 
in vivo animal 
studies  
 
MTX 
PC2:CHOL1; 
PC9:CHOL1: 
PC2.5:OA1 
80-
140 
In vitro newborn 
pig skin 
[101] 
tacrolimus 
2% Lipoid S 
100 
146 
In vitro SD rats 
skin 
[102] 
psoralen 
5% Lipoid S 
100/ 1.5% 
cholesterol 
198 In vitro rat skin [103] 
Cy A 
NAT 8539 
/ethanol 
(10/10) 
57 - 
101 
In vitro human 
skin 
[104] 
E
th
o
so
m
e
s 
tacrolimus 
2% Lipoid S 
100/ 30% eth-
anol 
85 
In vitro SD rats 
skin 
[102] 
psoralen 
5% Lipoid S 
100/ 40% eth-
anol 
120 In vitro rat skin [103] 
psoralen 
different rati-
os Lipoid S 
100/ ethanol 
56-
159 
In vitro rat skin; 
in vivo rat  
microdialysis 
assay 
[105] 
T
ra
n
sf
e
ro
so
m
e
s 
hydrocorti-
sone or 
dexame-
thasone 
 
 
SPC: 
oxyethylene: 
polysorbate 
100-
200 
In vitro porcine 
skin; in vivo 
mice 
[106] 
 
 
 Lipid particulate carriers have application in anti-psoriatic drug delivery due to drug 
pay load and increased stability. Table 2.7 presents some applications in treatment of PSO 
using lipid particulate carriers. 
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Table 2.7 - List of lipid-based particulate carriers for psoriasis topical therapy 
Carrier Drug Composition 
Size 
(nm) 
Skin pene-
tration tests Refs 
 
psoralen 
12% Precirol: 0.2% 
myverol or SPC: 
2.4% PF68 or Tween 
80 
297 
In vitro mice 
skin 
[96] 
S
L
N
 
dithranol 
Tricaprin/ soybean 
lecithin/ TDC 
230-264 - [107] 
tretinoin 
Myristyl myristate/ 
PF68/ chitosan 
163-285 - [108] 
dithranol 
Compritol 888 ATO/ 
Span60/ poloxamer 
407 
219 
 
- [109] 
tretinoin 
Phosphatidylcholine
/Tween 80/ BHT/ 
Compritol 
82 
In vitro mice 
skin; in vivo 
mouse tail 
model 
[110] 
capsaicin 
Compritol 888 ATO/ 
PC: PF68 
182 
In vitro rat 
skin; skin-
irritation 
test 
[111] 
 
mometasone 
furoate 
GMS/ Tefose-63/ 
Tween 80 
141-177 
In vitro mice 
skin 
[112] 
fluocinolone 
acetonide 
Compritol1 888 
ATO/ poloxamer 
188/ soya lecithin 
107 
In vitro goat 
skin 
[58] 
N
L
C
 
psoralen 
12% Precirol and/or 
squalene: 0.2% 
myverol or SPC: 
2.4% PF68 or Tween 
80 
173-210 
In vitro mice 
skin 
[96] 
tretinoin 
Phosphatidylcholine
/Tween 80/ BHT/ 
IPM/ Compritol 
79 
In vitro mice 
skin; in vivo 
mouse tail 
model 
[110] 
capsaicin 
Compritol 888 ATO/ 
Oleic acid/ PC: 
PF68 
145 
In vitro rat 
skin; skin-
irritation 
test 
[111] 
MTX 
Precirol ATO 5/ 
squalene/ Myverol/ 
PF68 
270 -320 
In vitro mice 
skin 
[113] 
MTX 
Witepsol1 S51/ ole-
ic acid/ Tween 60 
or Tween 80 
274–298 - [114] 
acitretin 
Precirol ATO 5/ 
oleic acid/Tween 
80 
223 
in vitro Hu-
man cadaver 
skin; Human 
clinical stud-
ies 
[64] 
 
 
      Emulsion based carriers involve the dispersion of two or more immiscible liquids stabi-
lized by a surfactant or emulsifier Table 2.8 presents the main application of this carrier in 
treatment of PSO. 
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Table 2.8 - List of lipid-based emulsion carriers for psoriasis topical therapy 
 
 
 
 Polymeric based carriers contain natural or synthetic polymer where polymer encap-
sulates drug. Self-assembled carriers include dendrimers, micelles, hydrogel and the main 
applications are shown in Table 2.9. 
 
  
Carrier Drug Composition 
Size 
(nm) 
Skin penetration 
tests 
Refs 
M
ic
ro
e
m
u
ls
io
n
 
 
8-
methoxsalen 
IPM and Tween 
80: Span 80: 
1,2-Octanediol 
190-1240 
In vitro newborn 
pig-skin 
[78] 
CyA 
Aerosol-OT/ 
Tween85/ IPM 
- 
In vitro rat skin; 
in vivo animals 
tests 
[123, 
124] 
ceramides 
Lecithin or 
TCPL4 
203-1279 
In vitro human 
skin 
[117] 
curcumin 
Eucalyptol/ 
polysorbate 
80/ ethanol 
2-5 
In vitro porcine 
skin 
[118] 
betame-
thasone 
dipropionate 
oleic ac-
id:sefsol/ 
Teween 20/ 
isopropyl alco-
hol 
60-190 
In vitro rat skin; 
in vivo animals 
tests 
[52] 
N
a
n
o
e
m
u
ls
io
n
 rice bran oil 
sorbitan 
oleate/PEG-30 
castor oil 
45-303 
In vivo clinical 
studies 
[119] 
paclitaxel 
Labra-
sol+vitamin E-
TPGS/ Labrafil 
M1944CS 
22 In vitro rat skin [120] 
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Table 2.9 - List of polymer-based self-assembled carriers for psoriasis topical therapy. 
Carrier Drug Composition 
Size 
(nm) 
Skin pene-
tration 
tests 
Refs 
d
e
n
d
ri
m
e
rs
 
8-
methoxyps
oralen 
PAMAM G3 and 
G4 
190-
1240 
In vivo rat 
skin tests 
[121] 
dithranol 
polypropylene 
imine (5.0 G) 
6-8 
In vitro rat 
skin; in 
vivo ani-
mals tests 
[122] 
m
ic
e
ll
e
s 
tacrolimus MPEG-dihexPLA 10-50 
In vitro 
human and 
porcine 
skin 
[123] 
CyA MPEG-dihexPLA 25-52 
In vitro 
human and 
porcine 
skin 
[124] 
h
y
d
ro
g
e
l 
CyA 
carboxyvinyl 
polymer/ pro-
pylene glycol/ 
diisopropanolam
ine/ 
polyoxyethylene 
glyceryl 
monostearate 
- 
In vitro rat 
skin 
[125] 
MTX 
acrylamide: 
acrylic acid 
monomers / 
terpenes/ etha-
nol 
- 
In vitro 
mice skin 
[126] 
MTX 
Propyl/ 
methylparaben/ 
carbomer/ 
triethanolamine 
- 
In vitro 
mice skin 
[127] 
tretinoin 
Carbopol® 
Ultrez 10 NF/ 
Imidazolidinyl 
urea 
- 
In vitro 
human skin 
[128] 
linseed Oil 
ethyl celulose/ 
sodium algi-
nate/ carbopol 
934/ carbopol 
971/ HPMC 
- 
In vitro rat 
skin 
[54] 
betame-
thasone 
dipropiona
te 
carbopol 934/ 
salicylic acid 
- 
In vivo 
animal 
tests 
[52] 
 
 
Particulate polymer carriers (nano e micro spheres) and capsular polymeric based car-
riers are described in Table 2.10. 
 
 
 
Table 2.10 - List of polymer-based particulate carriers for psoriasis topical therapy 
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Carrier Drug Composition Size (nm) 
Skin penetration 
tests 
Refs 
n
a
n
o
sp
h
e
re
s 
m
ic
ro
sp
h
e
re
s 
Trimethylpsoralen PLGA/ Tween 80 243 
In vitro hu-
man skin 
[37] 
Psoralen PLGA/ PVA 150–2900 
In vitro rat 
skin 
[38] 
Clobetasol propio-
nate 
PLGA/ PVA 
8000-
15000 
- [39] 
Naringenin and sericin  3875  [40] 
n
a
n
o
c
a
p
su
le
s 
     
Dithranol 
PCL/ Span® 
60/ Tween® 
80/ CCM 
230–250 - [41] 
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Chapter 3 - Methods 
 
 
 
3.1 Materials 
 
      Chemical reagents were adquired from Sigma-Aldrich (St Louis, MO, USA) unless stated 
otherwise. All chemicals and solvents were of analytical grade and therefore used without 
further purification. Aqueous solutions were prepared with double-deionized water (Arium 
Pro, Sartorius AG, Göttingen, Germany), which possesses conductivity values lower than 
0.1 μS cm-1. Fetal bovine serum (FBS), penicillin-streptomycin antibiotics mixture and Dul-
becco’s Modified Eagle’s Medium (DMEM) were purchased from Gibco® (Invitrogen Corpora-
tion, UK). L929 mouse fibroblast cell line was obtained from ATCC-LGC Standards (Barce-
lona, Spain) and HaCaT KC cell line was obtained from CLS (Eppelheim, Germany). 
 
A. Solid lipids  
Witepsol® E85 
      WITEPSOL E grades are hard fats with a melting range above body temperature, ap-
proximately 42–44°C [129]. They can be used to raise the melting point when associated 
with active ingredients that decrease the melting point. Also can be used as analgesics, 
anesthetics, antihypertonics and steroidal antirheumatics (corticosteroids). This lipid was 
kindly provided by Gattefossé (France)  
 
Cetyl palmitate 
 Cetyl palmitate (cetylis palmitas) is a wax produced by catalytic esterification of fatty 
alcohol (cetylic alcohol) and fatty acid (palmitic acid). Besides palmitic acid, cetyl 
palmitate may contain myristin acid and stearic acid. Cetyl alcohol may be partly replaced 
by myristyl alcohol or stearyl alcohol. Cetyl palmitate is a white, with waxy plates which is 
supplied as pellets or flakes. Pure cetyl palmitate crystallizes in two modifications melting 
at 45-52ºC. According to the composition of the ester mixture the melting point is in-
creased or decreased. Cetyl palmitate is practically insoluble in water, soluble in boiling 
ethanol and in methylene chloride, slightly soluble in light petroleum, practically insoluble 
in ethanol was kindly provided by Gattefossé (France) [130]. 
 
B. Liquid lipid  
Miglyol® 812 
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 Liquid lipids are fatty acid esters or alcohols (2-octyldodecanol). They are neutral car-
riers for various pharmaceutical applications. Because of their high polarity, they have 
superior solvent characteristics for active drugs [131]. Medium chain triglyceride 
(Triglycerida saturate media) is a synonym for Miglyol® 812. Consists of a mixture of tri-
glycerides, mainly caprylic acid and capric acid and is an at room temperature liquid lipid 
(oil) of low viscosity. Miglyol® 812 is a colorless till light yellowish oily liquid which is insol-
uble in water but miscible with dichloromethane, ethanol, petroleum ether and fatty oils 
purchased by Acofarma (Spain) [131].  
 
C. Surfactants 
PVA  
      PVA is produced commercially from polyvinyl acetate, usually by a continuous process. 
It is an odorless and tasteless, translucent, white or cream colored granular powder.  It is 
used as a moisture barrier film for food supplement tablets, food with inclusions that need 
to be protected from moisture uptake [132]. PVA is not known to occur as a natural prod-
uct. Typically a 5% solution of polyvinyl alcohol exhibits a pH in the range of 5.0 to 6.5. 
Polyvinyl alcohol has a melting point of 180 to 190°C [132]. 
 
Tween 80 
     Tween 80 or polysorbate 80 (polyoxyethylene sorbitan fatty acid ester). Like any 
polysorbate, are stable to electrolytes and weak acids and bases. Also, in common with 
other polyoxyethylene surfactants, prolonged storage can lead to the formation of perox-
ides. Very soluble in water; soluble in alcohol, cottonseed oil, corn oil, ethyl ace-
tate, methanol,toluene; insoluble in mineral oil [133]. It was used for the microemulsion 
which was applied on human skin, where polysorbate does not provoke irritations [133]. 
 
E. Psoriatic drugs 
Methotrexate 
 MTX is a folate antagonist that competitively bind to dihydrofolatereductase (DFHR) 
enzyme hampering cell growth and arresting cell cycle in G1/S phases [134]. MTX, the old-
est systemic therapy for PSO, still remains one of the most successful treatments for PSO 
and PSA that acts by suppressing the immune system and thereby stopping the inflammato-
ry response that can direct to PSO and psoriatic flares [77, 78]. MTX is one of the most ef-
fective therapeutic agents with a triple mode of action: it is anti-inflammatory, reduces 
cell proliferation and it is immunosuppressant. It is accessible to treat a variety of malig-
nancies, such as osteosarcoma, non-Hodgkin’s lymphoma, lymphocytic leukemia, 
choriocarcinoma, and head, neck, and breast cancers, against non-neoplastic conditions 
such as severe PSO and autoimmune diseases (e.g. RA) [13, 79, 80]. However, it causes 
numerous adverse effects (e.g. hepatotoxicity, ulcerative colitis, nephrotoxicity) that 
hampers its therapeutic application [13, 77]. MTX was kindly provided by Excella (Feucht, 
Germany) as a gift. 
 
Etanercept 
     Enbrel (etanercept) is a biologic medication that blocks TNF-α and other cells to cause 
inflammation. Enbrel helps lower the amount of TNF-α, which interrupts the inflammatory 
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cycle of PSO and PSA [135]. Approved in April 2004 by the U.S. Food and Drug Administra-
tion (FDA) for the treatment of moderate to severe plaque PSO. In January 2002, it was 
approved for PSA. It is also approved for treating RA [135]. 
 
 
3.2 Preliminary assessment of the production parameters in-
fluence on lipid nanoparticles 
 
 MTX solubilisation was studied in the presence of seven lipids (Cetyl Palmitate, Imwitor 
308, Lipocire™ CM, Witepsol® E76, Witepsol® E85, Witepsol® H32, Witepsol® S51). MTX sol-
ubilized in Cetyl Palmitate, Imwitor 308, Lipocire™ CM and Witepsol® E85 and no drug crys-
tals were observed (Table 3.1). So, the solid lipids Witepsol® E85, Lipocire™ CM and Cetyl 
Palmitate with a melting range above body temperature were selected to proceed with 
lipid nanoparticles production.  
 
Table 3.1 - Solubility of MTX in solid lipids. 
 
 
  
 
 
 
 
 
 
 
 NLCs were prepared using two different methods (1) ultrasonication  (Figure 3.1) and 
(2) emulsification-solvent evaporation technique using as liquid lipid (Miglyol® 812) and 
the surfactants: PVA, polysorbate 60 (P60) and polysorbate 80 (P80). After defining the 
production method (Figure 3.1) and the solid lipid, the optimization was based in varying 
the amount of drug, surfactant and sonication conditions, following a sequential procedure 
represented in Figure 3.2. The goal was to obtained a formulation with size bellow 200 
nm, as homogeneous as possible and with high drug entrapment efficiency (EE). 
 
 For the preparation of NLCs loaded with MTX two methods were considered as follow:  
(1) ultrasonication method: the aqueous phase containing the surfactant and 
the lipid phase with the drug were prepared separately by heating at 60ºC in a 
water bath, then the lipid phase was added to the aqueous phase. The mixture 
was then homogenized using a probe-sonicator and left to cool down at room 
temperature.  
 
(2) emulsification-solvent evaporation technique: the formulation was pre-
pared from an emulsion using as aqueous phase the surfactant in water and as 
oil phase the solid lipid, liquid lipid and the drug in the organic solvents di-
chloromethane (DCM) or dimethyl sulfoxide (DMSO). Then the emulsion was 
Solid lipid Dissolved MTX? 
Witepsol E76 - 
Witepsol E85 + 
Witepsol S51 - 
Witepsol H32 - 
Cetyl palmitate + 
Imwitor 308 + 
LCM + 
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subjected to ultraturrax (5 minutes) and probe-sonicator (10 minutes) produc-
ing a nanoemulsion. 
 
 
Figure 3.1 - Hot ultrasonication method for the production of NLCs. 
 
 Second step involved the choice of surfactant: P60, P80 or PVA while in the third 
stage consisted in the selection of solid lipid between Witepsol® E85, Lipocire™ CM and 
Cetyl Palmitate. The fourth and fifth steps were based on the evaluation of the influence 
of the amount of PVA surfactant (80, 100 and 120 mg) and (4, 20 and 40 mg) drug loading. 
 The sixth and seventh steps were related with sonication parameters such as time 
(10, 20 e 30 min) and amplitude (70 and 80%). At last, the ninth stage, evaluated the lipid 
ratio (solid/liquid: 70/30, 75/25 and 80/20).   
 Given the intended objectives, the final optimized MTX-loaded NLCs were prepared by 
hot ultrasonification with Witepsol® E85 (300 mg) and Miglyol® 812 (100 mg) in the lipid 
core, stabilized by the surfactant PVA (120 mg) and MTX at 10% (w/w) of total lipid mass. 
 The preparation required 10 minutes at 70% of amplitude as sonication parameters. 
 From this preliminary assessment it is clear the importance of several production pa-
rameters to produce the MTX-loaded NLCs. Based on this fact, a formulation design strate-
gy was implemented to optimize the production of the formulation. 
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Figure 3.2 - Representation of the optimization process. Highlighted are the conditions with the 
more adequate performance. 
 
 
3.3 Experimental design 
 
In order to obtain an optimized formulation is useful to evaluate the influence of sev-
eral parameters susceptible to affect the entire production process. A statistical experi-
mental design was implemented to assess the influence of the amount of liquid lipid, sur-
factant and MTX in the NLCs’s size, polydispersity and drug EE. 
 A full factorial design contains all possible combinations of a set of factors. In this de-
sign we performed total of 27 formulations with each coded level. Based on the results 
obtained a Box-Behnken experimental design was applied using 15 formulations at least 
three coded levels for each studied factor (Table 3.2) [146]. For each studied factor, the 
lower (-1), medium (0) and higher values (+1) were chosen on the basis of tested lower 
and upper values for each variable, according to pre-formulation studies and literature 
research. As we can see in the Table 3.2 coded levels are representative of the quantities 
of independent variables, X1, X2 and X3, amount of liquid lipid, surfactant and drug, re-
spectively. The data were analyzed using ANOVA by STATISTICA 10 (Statsoft®, Inc) soft-
ware. 
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Table 3.2 - Variables with respective coded levels of the Box-Behnken design.  
Factors Coded Levels 
 
Independent variables 
Low Level 
(-1) 
Medium Level 
(0) 
High Level 
(+1) 
X1 = Liquid lipid (mg) 40 50 60 
X2 = Surfactant (mg) 40 50 60 
X3 = Drug (mg) 2 10 20 
Dependent variables Constrains 
Y1 = particle size Optimum (250nm) 
Y2 = Polydispersity index Minimum 
Y3 = Entrapment efficiency Maximum 
 
  
 
The polynomial equation generated from the experimental design is given below:  
 
Y = b0 + b1X1+ b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + b11X1² + b22X2² + b33X3²  ,    (3.1) 
 
 
where Y is the dependent variable, b0 is the intercept, X1, X2, X3 are the coded levels of 
independent variables, and b1 to b33 are the regression coefficients computed throughout 
observed experimental values of Y; the terms X1X2 and Xi
2 (i = 1, 2 or 3) represent the in-
teraction and quadratic terms, respectively. The polynomial equation was statistically val-
idated using ANOVA, by statistical significance of coefficients and r2 values. Statistical 
analysis were considered significant when the p values were ≤ 0.05. 
 
 
3.4 Optimization and validation 
 
 The graphical and numerical analyses were done in order to obtain optimum values of 
the studied variables. The optimum variables were used to prepare a checkpoint NLC for-
mulation and were compared with the predicted values to calculate the predicted error, in 
order to validate the chosen experimental domain and polynomial equation. Validation of 
this method was based on the formulation obtained throughout medium coded levels that 
correspond at sample #14 that is the formulation at central point, for estimating the ex-
perimental error. Optimized formulation was prepared in triplicate according to the ob-
tained results after conclusion of this experimental design respecting the established cri-
teria. 
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3.5. Determination of particle size, size distribution and sur-
face charge  
 
Theoretical principles 
 
 Particle size analysis can be achieved by dynamic light scattering (DLS) also called 
Quasi-Elastic Light Scattering (QELS) or Photon Correlation Spectroscopy (PCS) because 
when photons are scattered by mobile particles, the process is quasi-elastic [136]. This 
method was performed using a Brookhaven ZetaPALS DLS equipment, suitable to deter-
mine size and size distribution (polydispersity index, PDI) of particles with great accuracy, 
in a reduced time and as a non-invasive technique [106, 107, 145]. 
 DLS technique measures the translational diffusion coefficient through interactions 
between a dispersion and a laser beam. Therefore disperse particles in a diluted suspen-
sion without interactions between particles moving to thermal Brownian movement or mo-
tion (random movement of the particles owing to bombardment by the solvent molecules 
that surround them) and so the size of the particles should be calculate using Stokes-
Einstein equation [145, 146]. 
 
   
    
     
        
      
     
    ,                                     (3.2) 
 
where Dh is hydrodynamic diameter value allows to calculate size particle, Dt is transla-
tional diffusion coefficient (we know this through DLS) , Kb is Boltzman´s constant (we 
know this), T is thermodynamic temperature (we control this) and η is dynamic viscosity 
(we know this) 
 This coefficient will depend not only on the size of particle but also concentration and 
type of ions in the medium [139]. 
 
 Particle size distribution can be determined by analyzing the intensity of the scattered 
light as a function of angle between the incident and scattered beams using a suitable 
light scattering theory [140]. 
 The size distribution is very important to determinate the physical stability of nano-
suspensions. This parameter represents the quality of dispersion assessing the homogeneity 
of the size distribution of particles in solution [148, 149]. PDI is used to describe the width 
of the size distribution and the accurate value of this parameter for a homogeneous nano-
particles population  is below 0.3 [150, 151]. 
 
 Particle surface charge, also known as zeta potential (ζ-potential) and represented on 
Figure 33 , is the electrical potential that reflects the surface charge of nanoparticles in 
an aqueous medium. It is defined such as the distance away from the particle surface be-
low the ions keep tightly attached to the particle when it moves through an electrical field 
[144]. 
 Due to gravity or an electric field, the particles and ions move in the solution. The hy-
drodynamic shear is the region, or the slipping plane, the ions do not move with the parti-
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cles. The electric potential at the slipping plane is called zeta potential, ζ-potential [145]. 
Generally, the ζ-potential values of -30 or +30 mV are considered to be sufficient and ade-
quate for stabilization of NLCs [146]. 
 
 For the ζ-potential measurement a laser Doppler electrophoresis is used to calculate 
the net velocity through an electric field applied to the nanoparticles [145, 155]. This pro-
cedure involves the Henry approximation: 
 
 
  
   
   
       ,                                                                         (3.3)  
where:  
ζ - zeta-potential (main goal)  
μ - electrophoretic mobility,  
ε - dialectric constant,  
η - viscosity of the water (in this case) 
f (kr) - Henry function.  
 
This function generally has value of 3/2 or 1 depending the Smoluchowski or Huckel ap-
proximation, respectively. To measure ζ-potential in this case, this term assumes the value 
3/2 because is used an aqueous solution [145, 155]. 
 
Figure 3.3 - Representation of the surface potential measurement. (Adapted from [148]) 
 
 
 Experimental details  
 For each formulation a dilution of 1:400 was made using double deionized water fol-
lowed by determination of particle size, PDI and ζ-potential at 25ºC using ZetaPALS 
(Brookhaven 153 Instruments Corporation, Holtsville, NY, USA). Photon correlations of 
spectroscopic measurements were carried out at a scattering angle of 90° with 10 cycles 
and 6 runs for each measure. 
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3.6 Entrapment efficiency 
 
Theoretical principle 
 
 EE is defined as the ratio of entraped drug within the nanoparticles to total amount of 
drug used to formulate the NLCs[105, 157]. In this study, the drug EE was determined indi-
rectly using the following equation [105, 157, 158]. 
 
        
                                  
            
      ,                                (3.4) 
 
      Absorption spectroscopy was used in order to determine the concentration of non-
incorporated MTX [151]. 
      This process, commonly referred to as spectrophotometry is one of the most flexible 
analytical method that allows measuring the non-incorporated drug through the amount of 
the light absorbed by a sample at a defined wavelength [152]. Transmittance (T) is defined 
as the ratio between incident radiation transmitted by the analyte and reference solutions 
(Figure 3.4) [152]. 
 
Figure 3.4 - Representation of the Beer Lambert law. (Adapted from [152].) 
 
 
Experimental details  
 The MTX-loaded NLCs containing the entraped drug was retained in Amicon filter 
(Merck millipore, Germany) while the non-incorporated MTX remained in the supernatant. 
 The supernatant samples were analyzed using UV-vis spectrophotometer at λmax 303 nm, 
which is the maximum absorption of MTX in aqueous solution [113]. A standard curve of 
MTX in water was used to determine the amount of the non-incorporated MTX and the EE. 
 
 
3.7  Transmission electron microscopy  
 
Theoretical principles 
 
  When electrons increase speed up to elevated energy levels and focused on a ma-
terial, they can disperse or backscatter elastically or inelastically, or produce numerous 
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interactions, source of different signals such as X-rays, Auger electrons or light. Transmis-
sion electron microscopy (TEM) is a fundamental characterization tool for directly imaging 
nanomaterials to achieve quantitative measures of particle and/or grain size, size distribu-
tion, and morphology (Figure 3.5).. Successful imaging of nanoparticles by TEM depends on 
the contrast of the sample comparative to the background [161, 162]. 
 
Figure 3.5 - TEM Jeol JEM 1400 microscope. 
 
Experimental details  
 The shape and size of all of lipid nanoparticles was observed by TEM using a Jeol JEM 
1400 microscope. Prior to analysis, samples were diluted with double deionized water, 
loaded on nickel grids with 300 mesh, dried at room temperature and stained with uranyl 
acetate for 30 seconds for contrast and then placed at the accelerating voltage of 60 kV. 
 
 
3.8 Cryo-scanning electron microscopy 
 
Theoretical principle 
 
     Cryo-SEM is an effective technique of imaging of samples containing moisture without 
causing drying artifacts. It is a quick and reliable way to overcome SEM preparation prob-
lems. There is a cryo chamber that embody a resistance heating vacuum evaporator to 
coat samples with gold. There are heaters that sublime the ice molded in samples. Then, 
liquid nitrogen needs to be quickly added to the samples to frozen them and finally loaded 
into the Cryo-SEM[155].   
 
 
Experimental details  
 The morphology of nanoparticles was evaluated by cryogenic-scanning electron micros-
copy (cryo-SEM) using the experimental facilities at the Materials Centre of the University 
of Porto, Portugal (CEMUP). All lipid nanoparticles were filtered through a 0.80 µm filter 
to remove impurities of the water. A volume of these dispersions was dropped on an ade-
quate support and rapidly cooled by plunging into sub-cooled nitrogen (slush nitrogen) and 
transferred under vacuum to the cold stage of the preparation chamber. Cryofactures 
were then performed using an ALTO 2500 (Gatan Alto 2500 (Pleasanton, CA, USA)), with 
subsequent sublimation for 180 seconds at -90ºC and coating with Au/Pd by sputtering for 
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35 seconds. Then, the samples were transferred to the Cryo-SEM chamber and observed at 
a temperature of -150ºC using a JSM 6301F microscope (JEOL, Tokyo, Japan). 
 
 
3.9 Fourier transform infrared (FT-IR) spectroscopy  
 
Theoretical principle 
  
      FT-IR measures the intensity of the infrared absorption radiation by a sample at a spe-
cific wavelength [156]. Some of the infrared radiation is absorbed by the sample and some 
is transmitted resulting in a spectrum that characterizes the molecular absorption and 
transmission; thus creating a molecular 'fingerprint' of the sample [157]. 
 This technique can identify unknown materials, demonstrate if an compound is present 
in a solution and determine the amount of components in a mixture [157]. Furthermore, 
this method provides a fast and precise measurement [164, 165].  
 
 
Experimental details  
 Prior FT-IR analysis the samples were lyophilized (LyoQuest-85 plus v.407, Telstar). 
 The freeze-dried optimized formulations of SLNs/NLCs with and without MTX, pure 
MTX, as well the used combinations as physical mixtures, were evaluated using an FT-IR 
Spectrophotometer (FrontierTM, PerkinElmer; Santa Clara, CA, USA) equipped with a hori-
zontal attenuated total reflectance (ATR) sampling accessory with a diamond crystal. All 
samples were run in triplicate. At the first, we performed a background run (to remove 
the background noise of the instrument) and use a run with pure MTX as positive control. 
 The data was obtained for the mid-infrared absorbance region, between 4000 and 600 
cm-1, and the spectra were measured at a spectral resolution of 4 cm-1 with 200 scans co-
added, to minimize differences between spectra due to baseline shifts. In order to per-
form the spectra comparison, spectra were truncated at 2000 and 750 cm-1, based on the 
typical absorption bands for the analyzed compounds.  
 
 
3.10 Storage stability 
 
 Stability of nanoparticles during storage was assessed by the appearance, size, PDI and 
drug content in comparison to the day of production. NLCs dispersions were stored after 
production in closed glass vials at room temperature and examined on the day of produc-
tion and after 4 or 6 weeks of storage.  
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3.11 Targeted lipid nanoparticles for psoriasis 
 
Theoretical principle 
 
 Functionalization is the procedure applied in surface engineering field to introduce a 
chemical functional group on the surface of the nanoparticles [158]. This targeting ap-
proach can improve nanoparticles efficacy and minimize the side effects of drugs because 
it results in an active targeting towards the target cell/ tissue [166–168]. Active targeting 
can be performed by an antibody, a peptide and can revolutionize the therapeutic poten-
tial offered by local topical therapy, particularly, in PSO [160]. 
 In this work, the lipid nanoparticles were functionalized with a model globular protein 
(bovine serum albumin, BSA) and a monoclonal antibody (etanercept) (Figure 3.6). BSA is 
used in numerous biochemical applications due to its stability and lack of interference 
within biological reactions The monoclonal antibody, etanercept, is a fully human tumour 
necrosis factor (TNF) soluble receptor fusion protein that antagonizes the effects of en-
dogenous TNF and it is approved to treat moderate-to-severe PSO cases where current sys-
temic therapies have failed [161]. This two molecules were coupled throughout 
carbodiimide reaction using  as a crosslinker, the water-soluble 1-etliyl-3-(3 
dimethylaminopropyl) carbodiimide (EDC) and DSPE-PEG-NH2 that was previsouly incorpo-
rated in the nanoparticles [162].  
 
Figure 3.6 - Functionalization process of the lipid nanoparticles. 
 
 This procedure was performed according to carbodiimide method [163]. The coupling 
of the molecule of interest was carried out in PBS buffer in a three-step procedure. The 
first step consists in the activation of the carboxyl-groups. EDC is a powerful cross linker 
for peptides and proteins for use in numerous protein and cell biology detection and analy-
sis methods that and reacts with various forms of amides and hydroxyl functional groups 
that's why with carboxylic groups to form an active O-acylisourea intermediate [171, 172]. 
 The second step was the reaction of the amine function with the activated carboxylic 
functions [164]. The last step consists of binary covalent binding of an antibody with the 
lipid nanoparticles. 
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Experimental details  
 For targeting purposes, lipid nanoparticles were also performed by the  
ultrasonication method. Briefly, the lipid phase was prepared by melting 150 mg of Cetyl 
Palmitate, 45 mg of Miglyol®812 and 18 mg of MTX with an aqueous phase composed by 47 
mg of polissorbate 80 in 7 mL of double-deionized water. For the functionalization, 5 mg 
of DSPE-PEG-NH2 were added to the lipid phase. Both phases were heated to 60ºC in a wa-
ter bath, separately. The aqueous phase was poured into the lipid phase and homogenized 
using a probe-sonicator (VCX130, Sonics & Materials, 115 Newtown, CT, USA) with ampli-
tude frequency of 70% during 10 minutes, in order to obtain a nanoemulsion. Empty lipid 
nanoparticles were prepared in a similar way, without the drug. Similarly, SLN were pre-
pared without the addition of the liquid lipid, Miglyol®812. Then, formulations were left to 
cool down at room temperature. Then, in another tube 100 g of EDC were added in 200 
mL of PBS mixed with the DSPE-PEG-NH2 containing lipid nanoparticle, by vortex, and 
placed for 30 minutes at 4ºC. Then, 10 L of Etanercept or BSA (corresponding to 500 g) 
were added to 3.5 mL of nanoformulations/EDC solution. Fuctionalized nanoformulations 
were placed at 4ºC until further use. 
 
 
3.12  Coupling efficiency of the functionalization 
 
Theoretical principle 
 
 To determine the quantity of antibody or protein conjugated at surface of nanoparti-
cles was used a commercial kit the BioRad™ DC Protein Assay Synergy™ HT Multi-mode 
microplate reader (BioTek Instruments Inc., Winooski, VT, USA). This is a colorimetric as-
say based on Biuret reaction for the determination of protein concentration [165]. Peptide 
bonds of proteins react with copper under alkaline conditions to produce Cu+, which reacts 
with the Folin reagent through the Folin Ciocalteau reaction. The reactions result in a 
strong blue color, with maximum absorbance at 750 nm and minimum absorbance at 405 
nm, which depends partly on the tyrosine and tryptophan content. The method is sensitive 
down to about 0.01 mg of protein.mL-1, and is best used on solutions with concentrations 
in the range 0.01–1.0 mg.mL-1 of protein [173, 174]. 
 
 
Experimental details  
In this work we used a Etanercept such a protein of interess due to its use in bio-
logical treatment of psoriasis and BSA for costs reasons and also be a protein it will have a 
similar behavior [167]. 
The procedure was based on the kit instructions. Briefly, standard solutions of BSA 
were prepared between 1.5 – 0.09 mg.mL-1. To a 96-well plate 5 μL of each standard and 
samples were transferred in five replicates. After adding the reagents A and B the optical 
density was read in a Biotek (Sinergy HT) microplate reader. To determine the protein 
concentration, the absorbance at 750 nm was measured and compared with a blank con-
taining the same amount of dye [168]. 
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3.13 In vitro drug release 
 
Theoretical principle 
 
 Dialysis is a powerful technique to separate biomolecules according to their molecular 
weight and can also be used to evaluate the compound release from the nanoparticles and 
in binding studies [169]. This method, separate biomolecules across a 'semi-permeable' 
membrane constituted by pores that retain the biggest molecules and is permeable at 
small molecules [170]. 
 The dynamic release has been used to measure the drug release kinetics from the lipid 
nanoparticles. In this process, the  drug release is achieved by diffusion across the dialysis 
membrane while nanoparticle-bound drug is prevented to pass through the membrane [179, 
180]. 
 
 
Experimental details  
 The optimized formulation was subjected to in vitro release studies using 80 mL of 
phosphate buffer at pH 7.4 or acetate buffer at pH 5 as dissolution medium (maintained at 
37 ± 0.5°C and 32 ± 0.5°C), which is equivalent to the pH of the skin and inflamed skin 
respectively. In vitro release studies were performed using the dialysis bag method, modi-
fied to maintain a sink condition and achieve satisfactory reproducibility, as illustrated in 
Figure 3.7. 1.5 mL of MTX-loaded NLC dispersion containing 250 μg of MTX was first poured 
into the dialysis bag (molecular weight cut off 6,000–8,000 Daltons, CelluSep1 T2; Mem-
brane Filtration Products Inc., Frilabo, Portugal) with the two ends fixed by thread and 
placed into the preheated dissolution media. The suspension was stirred at defined tem-
peratures, using a heating and magnetic stirring plate (IKAMAG1, Staufen, Germany) at 350 
rpm. One mL of the sample was withdrawn at fixed time intervals and the same volume of 
fresh medium was added accordingly. The drug content determined 
spectrophotometrically (Jasco V-660 spectrophotometer, USA), using a standard curve of 
MTX in phosphate buffered saline (PBS) pH 7.4 and acetate buffer pH 5. The mathematical 
models for evaluation of drug release kinetics: zero order, first order, Higuchi, Peppas-
Korsmeyer and Hixon-Crowell were fitted to the experimental data [173]. Regression coef-
ficient (r2) was calculated to determine the best-fit model. 
Figure 3.7 - Image representing the setup of an in vitro drug release assay. 
 
 62 
 
 
 
3.14 Cell culture and viability assessment  
 
Theoretical principle 
 
 Cell viability and cytotoxicity assays are used for drug screening and toxic assessment 
of a certain chemicals or formulation. They are based on various cell functions such as en-
zyme activity, cell membrane permeability, cell adherence and nucleotide uptake activity 
[174]. 
 In this work we used an enzyme-based viability methods, the MTT assay, to evaluate 
cell viability. It is based in the reduction of the mitochondrial dehydrogenases activity 
(Figure 3.8) [174]. MTT is reduced  to purple crystals of formazan [174]. 
Figure 3.8 - Principle of the MTT assay. 
 
Experimental details  
 Murine fibroblasts L929 from the American Type Culture Collection (Rockville, MD, 
USA) and HaCaT (human KC) were cultured in DMEM supplemented with 10% (v/v) FBS and 
1% (v/v) penicillin-streptomycin. The cells were maintained in a humidified chamber at 
37°C and 5% CO2, and the cells were detached using a scraper when reaching 80% conflu-
ence. For assessment of the formulations effect on the cell viability a MTT assay was per-
formed. Cells were cultured in 96-well plates at 5x104 cells.mL-1 density and after 24-hours 
incubated with the all the lipid nanoparticles at different concentrations (ranging from 
0.1-100 μg.mL-1 in MTX). Empty lipid nanoparticles were added at equivalent lipid concen-
tration to the MTX-loaded lipid nanoparticles (15-250 μg mL-1). Upon 24 or 48 hours of in-
cubation, the culture medium was removed and replaced by 100 μL of MTT at 0.5 mg mL-1 
in fresh culture medium. The plate was incubated for 3 hours at 37°C and formazan crys-
tals were solubilized using 100 μL of DMSO. The absorbance (590 nm, 630 nm) was read 
using a Synergy™ HT Multi-mode microplate reader (BioTek Instruments Inc., Winooski, VT, 
USA).  
 
3.15 Skin permeation studies 
 
Theoretical principle 
 
 The assessment of molecules penetration through the skin is a crucial point in the 
evaluation and selection of drugs/ formulations for dermal or transdermal application 
[183, 184]. Several ex vivo and in vitro skin models with similarities with human skin, are 
frequently used to assess drug skin permeation profiles and kinetic parameters [175]. Also, 
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a wide range of animal models have been suggested as a suitable replacement for human 
skin such as primates, porcine, mouse, rat, guinea pig and snake models [175]. 
 Anatomically and physiologically, pig skin is analogous to human skin. Indeed, pig SC is 
comparable to human SC in terms of lipid composition and the human viable epidermis is 
around 70 μm and the pig’s from 66-72 μm [183, 185, 186]. 
 
 
Experimental details  
 To assess MTX permeation through the skin, samples of pig ear skin were mounted on 
standard Franz diffusion cells (Figure 3.9). The skin permeation of MTX, MTX-loaded 
NLCs/SLNs, void NLCs and functionalized-MTX loaded NLCs/SLNs were evaluated using a 
Franz cell assembly (9 mm unjacketed  Franz Diffusion Cell with 5 mL receptor volume, o-
ring joint, clear 216 glass, clamp and stir-bar; PermeGear, Inc., USA) [179]. The donor 
medium consisted of vehicle containing either free MTX or loaded on lipid nanoparticles 
systems, with an equivalent amount of 250 μg of MTX. In the receptor medium (4.7 mL) 
phosphate buffer, pH 7.4 containing 10% DMSO, added to maintain sink conditions. The 
available diffusion area between cells was 0.64 cm2. The stirring rate and temperature of 
receptor were respectively kept at 600 rpm and 32±0.5ºC. At appropriate intervals, 500 μL 
aliquots of the receptor medium were withdrawn and immediately replaced with equal 
volumes of fresh buffer. The cumulative amounts of MTX permeated through the skin was 
determined by HPLC.  
 The quantification of MTX was conducted by HPLC rather than UV–vis spectrophotome-
ter to overcome interferences from skin components released during the experiment. The 
HPLC system included MD-2015 multi-wavelength detector (Jasco, Easton, MD, USA) pro-
grammed for peak detection at 303 nm, a high-pressure pump (PU-2089), an autosampler 
(AS- 235 2057) and a controller (LC-Net II/ADC) mastered by ChromNAV software. A 
Chromolith 4.6-mm reversed-phase monolithic column (Merck, Darmstadt, Germany) con-
nected to a guard column of the same material was used as a stationary phase. The MTX 
quantification was performed according to method previously described [180]. In particu-
lar, standard MTX solutions were prepared at 0.75, 1.5, 3, 6, 12.5, 25, 50 and 100 μg.mL-1 
in mobile phase and in permeation buffer enriched upon pig skin contact for defined times 
(1.5; 3; 4.5; 6 and 8 h). 
 Percentage of permeation of MTX through the skin was calculated by the next equation 
[181]. 
 
Permeation  %  
Drug amount in the receptor compartment
Drug amount in the donor compartment
 100    ,                             (3.5) 
  
 Flux of MTX through the skin was obtained by applying the finite flux equation: 
 
  
 
   
 ,                                                               (3.6) 
 
where Q corresponds to the quantity of MTX traversing the skin in time t, with A being the 
area of exposed skin in cm2 (in our study 0.64 cm2, as previously stated). 
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Figure 3.9 - Image of our skin permeation studies. 
 
 
3.16 Hydrogel enriched with lipid nanoparticles 
 
Theoretical principle 
 
 Currently, hydrogel enriched with nanoparticles have gained substantial attention as 
one of the most promising nanoparticulate drug delivery systems since it combines the 
characteristics of a hydrogel such their hydrophilicity, flexibility, versatility, high water 
content with the small size of nanoparticle [182]. 
 Hydrogels are by definition polymeric networks with three-dimensional configuration, 
cross-linked with amounts of water or biological fluids. Their affinity to absorb water is 
attributed to the presence of hydrophilic groups in polymers forming hydrogel structures 
which allow chemical and biochemical modification resulting in many kinds of biopolymer-
based materials. Due to their properties such good compatibility with tissues, ease of ap-
plication and preparation, low cost, softness and excellent biocompatibility, hydrogels 
have been widely used in pharmaceutical and cosmetic applications. Their major disad-
vantage is their low mechanical strength [182]. Therefore, hydrogel was chosen in this 
work as a topical dosage form to add value for the topical therapy of PSO. 
 Carbomer is one of the polymers generally used in preparation of hydrogels with phar-
maceutical applications. Carbopol® (made of carbomers) polymers are anionic polymers of 
acrylic acid, cross-linked. They are used as thickening, dispersing, suspending and emulsi-
fying agents in pharmaceuticals and cosmetics [182], [183]. Their neutralized aqueous dis-
persions demonstrate high viscosity that decrease the turbidity of the dispersion and con-
siderably increases its consistency. This occurs because the polymer chains elongates un-
der the influence of electrostatic repulsion forces [182]. Specifically, Carbopol® 934, 940 
and Ultrez 10 were reported by many to be of great applications pharmaceutically and 
cosmetically [184]. 
 
 
Experimental details  
 Hidrogels were produced using Carbopol® 934: a certain amount of polymer was hy-
drated in 25 mL of double-distilled water using a stirrer at a speed of 150 rpm overnight 
(Figure 3.10A).  
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Figure 3.10 - Preparation of hydrogel. A) Carpobol hidratation B) NaOH neutralization. 
 
NaOH solution (10%) was added dropwise to neutralize the solution until a transparent 
gel appeared and to confer a pH value within the range to 5.5-7.4, similar to the dermal 
conditions (Figure 3.10B).  The pH was confirmed with universal pH strips. Because lipid 
nanoparticles suspension is liquid, different amounts of carbopol (Table 3.3) were tested 
in the hydrogels preparation. The gel with the concentration of carbopol that had the best 
consistency considering its spreadability and rheological behaviour was chosen, to incorpo-
rate the drug-loaded and void lipid nanoparticles functionalized and without functionaliza-
tion. 
 
Table 3.3 - Different concentration of carbopol® tested to prepare 25 g of hydrogel 
 
Gel 1 Gel 2 Gel 3 Gel 4 
Carbopol® 934 
(w/w%) 
0.5 1 1.5 2 
Double distilled 
water 
25 mL 
NaOH solution 
(10%) 
q.b to neutralize different concentrations of carbopol 
 
 
3.17 Hydrogel characterization 
 
Theoretical principle 
 According to the definition, “Rheology is the science of the flow and deformation of 
matter under the effect of an applied force” that describe flow behavior through the vis-
cosity, elasticity, and plasticity of liquid, solid and semisolid materials under physical de-
formations. [137, 138]. Rheological measurements provide useful information about inter-
actions between nanostructures, vehicles and/or active compounds [138]. Viscosity is a 
measure of the internal resistance against flow [138,193]. The relation between viscosity 
and shear rate reveals the nature of the system which can be Newtonian or non-Newtonian 
(Figure 3.11) 
 
 66 
 
 
 
 
Figure 3.11- Non-Newtonian and Newtonian fluids. a) Non newtonian-time dependent b) Non 
newtonian-time independent behaviour. Adapted from [186]. 
 
 A system is said to have Newtonian flow behavior when its viscosity is independent of 
shear rate, while in a non-Newtonian flow system the viscosity changes according to the 
rate of shear [139, 195]. Furthermore, Non-Newtonian systems can be viscoelastic, time-
dependent (thixotropic or rheopectic) or time independent (plastic, pseudoplastic or dila-
tant) [140].  
 The time-dependent change in viscosity is the most wanted property in the pharma-
ceutical formulations due to their requirement of the flexibility in drug delivery and par-
ticularly thixotropy (rheological manifestation of viscosity exhibited by the pseudoplastic 
systems) is one of the most important property for topical applications of drugs. It repre-
sents phenomenon of the fluid which shows a reversible structural transition [188]. 
 In viscosity measurements, Yield stress (τ0) of a material can be defined as the mini-
mum stress above which flow can be observed. Therefore, hydrogels or creams can be 
added to the liquid solid lipid dispersions and it gives rise at convenient dosage to obtain a 
topical application form [189]. 
 Incompatibilities with ingredients from the hydrogel may occur due to interactions be-
tween the gel forming polymer, emulsifying agents, lipid and drug [198, 199] . Thus, its 
rheological studies are crucial in the development of a potential new drug delivery system 
for topical use because them can affect the semisolid consistency of the topical formula-
tion [191]. Furthermore, the viscous and elastic properties of the dispersions are im-
portant for their application to skin [192]. 
 
 
Experimental details  
 Rheological measurements of the developed hydrogels were performed on a 
viscosimeter (Therme Haake VT550) equipped with a cone and plate test geometry (plate 
diameter 20 mm, cone angle 4º). All measurements were carried out at a temperature of 
20 ± 0.1°C. The rheological properties were studied by continuous shear investigations, 
which were performed in order to evaluate the shear stress [Pa] as a function of shear rate 
[1/s]. The determination mode was set to flow-step measurement with shear rates from 0 
to 500 1/s and back again to 0 1/s. The resulting shear stress and viscosity were measured. 
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3.18 Statistical analysis 
 
 Data is expressed as the mean ± standard deviation, for a minimum of three independent 
experiments. Statistical comparisons of the means were performed using one-way analysis of 
variance or Student’s t-test with Welch’s correction, Mean ± SD (n=3); * p<0.05, **p<0.01 ob-
tained with one-way ANOVA analysis with GraphPad Prism 6 software (La Jolla, California, 
USA). The differences were considered to be significant when the P-value was < 0.05. 
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Chapter 4 - Results and discussion 
 
 
 
4.1 Optimization of nanostructured lipid carriers loaded with 
methotrexate 
 
Initial steps for formulation of MTX-loaded NLCs assessed the drug solubility in the sol-
id lipids. Six lipids with different physicochemical properties were studied and MTX solubil-
ized in Cetyl Palmitate, Imwitor 308, Lipocire™ CM and Witepsol® E85 with no drug crystals 
observed. So, the solid lipid Witepsol® E85 with a melting range above body temperature 
and exhibiting the higher solubility was selected to proceed with the optimization proce-
dure.  
Preliminary batches of NLCs were prepared to identify possible factors influencing the 
incorporation of MTX on NLCs, their size and polydispersity. The parameters studied were 
speed and time of sonication, type and amount of surfactant and optimum lipid loading in 
10 mL of dispersion. Based on the preliminary formulation studies, three major variables 
affecting the particle size and drug EE of NLCs were identified: amount of liquid lipid, 
amount of surfactant and amount of drug. 
 
4.1.1 Experimental design 
 
 Twenty seven experimental runs were conducted using full factorial analysis with a 
triplicate of the central point for estimation of the experimental error. The results could 
be shown in Table 4.1. 
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Table 4.1 - Formulation composition and the effect on different formulation variables on particle 
size (Y1), polydispersity index (Y2) and entrapment efficiency (Y3) according full factorial design. 
Sample Factors Responses 
X1 
(mg) 
X2 
(mg) 
X3 
(mg) 
Y1 (nm) Y2 Y3 
(%) 
1 40 40 2 257.9 0.066 67 
2 40 40 10 275.9 0.079 92 
3 40 40 20 258.6 0.067 95 
4 40 50 2 261.2 0.073 65 
5 40 50 10 275.4 0.072 91 
6 40 50 20 263.4 0.089 95 
7 40 60 2 261.8 0.078 68 
8 40 60 10 273.9 0.055 89 
9 40 60 2 258.4 0.052 95 
10 50 40 2 257.2 0.09 65 
11 50 40 10 282.9 0.033 89 
12 50 40 20 266.6 0.062 95 
13 50 50 2 286.1 0.051 66 
14 50 50 10 265.5 0.088 89 
15 50 50 20 285.4 0.039 95 
16 50 60 2 242.3 0.062 61 
17 50 60 10 239.8 0.091 89 
18 50 60 20 255.5 0.085 90 
19 60 40 2 290.3 0.042 54 
20 60 40 10 291.7 0.058 90 
21 60 40 20 284.2 0.041 94 
22 60 50 2 243.7 0.108 60 
23 60 50 10 262.2 0.067 89 
24 60 50 20 256.5 0.092 94 
25 60 60 2 260.8 0.056 52 
26 60 60 10 257.4 0.084 58 
27 60 60 20 275.2 0.069 88 
       
 
 
 Fifteen experimental runs were conducted using Box-Behnken design with a triplicate 
of the central point for estimation of the experimental error (Table 4.2)..  
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Table 4.2 - Formulation composition and the effect on different formulation variables on particle 
size (Y1), polydispersity index (Y2) and entrapment efficiency (Y3) according Box-Behnken design 
 
 Statistical analysis and calculated p-values were determined together with the fitting 
mathematical model involving the individual main effects and interaction factors are 
shown in Table 4.3. The positive sign before a factor revels that this response increases 
whereas the negative sign indicates that the response decreases with the factor. Interac-
tion terms or quadratic relationships are represented by more than one factor or higher-
order terms in regressions equations, respectively. It is also suggested non-linearity be-
tween factors and responses. A factor can produce a different degree of response when a 
factor is varied at different levels or more than one factor is varied simultaneously. The 
intercept correspond to the mean of the responses. Analysis of variance for the relevance 
of the model are shown in Table 4.4, where the model is statistically significant when F is 
higher that Fcritic for all responses. 
 
Effect on Particle Size 
 The particle size ranged from 242.3 nm (sample 10) to 291.7 nm (sample 2), with the 
selected levels of variables, while the mean was found to be 262.3 nm, which is the inter-
cept of the model (Table 4.3). The most significant factors affecting particle size are the 
amount of surfactant (X2) and amount of drug (X3
2) (p<0.05). The amount of surfactant had 
a negative effect on particle size i.e, higher quantaties of surfactant gave rise a smaller 
size of particles. Higher amounts of surfactant may promote formation and stabilization of 
smaller particles due to the decrease in interfacial tension between the lipid and the ex-
ternal phase [193]. On the other hand, drug concentration has a positive effect, as ex-
pected, due to the rise molecular density in the inner phase. Interaction terms have non-
statistically significant effects on Y1. 
Sample 
Factors Responses 
X1 (mg) 
 
X2 (mg) 
 
X3 (mg) 
 
Y1 (nm) 
 
 Y2 
 
Y3 (%) 
1 40 40 10 275.9 0.079 92 
2 60 40 10 291.7 0.058 90 
3 40 60 10 273.9 0.055 89 
4 60 60 10 257.4 0.084 58 
5 40 50 2 261.2 0.073 65 
6 60 50 2 243.7 0.108 60 
7 40 50 20 263.4 0.089 95 
8 60 50 20 256.5 0.092 94 
9 50 40 2 257.2 0.090 65 
10 50 60 2 242.3 0.062 61 
11 50 40 20 266.6 0.062 95 
12 50 60 20 255.5 0.085 90 
13 50 50 10 265.5 0.088 89 
14 50 50 10 250.0 0.069 88 
15 50 50 10 269.9 0.087 88 
 71 
 
 
 Despite the significant effect of variables on particle size, and a correlation coefficient 
not as high as expected (r2 0.863), the relatively small ranges of the responses support 
that the hot ultrasonication method is relatively robust to factor changes. 
 
Table  4.3 - Summary of results of regression analysis for responses Y1, Y2 and Y3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect on Polydispersity index 
 The PDI ranged from 0.055 (sample 3) to 0.108 (sample 6) (Tables 4.1 and 4.2), while 
the mean was 0.078 according to the model intercept (Table 4.3). The only independent 
factor that seemed to influence on PDI is the amount of surfactant (X2) since all the ef-
fects involving this variables were statistically significant (Table 4.3). The PDI value in-
creases with the increase of surfactant concentration, probably in a non-linear relationship, 
as the p-value of the linear coefficient (X2
2) was <0.05. In addition, the interaction terms 
involving the amount of surfactant (X1X2 and X2X3) are also significant (p<0.05). This phe-
nomenon may be explained by the adsorption of PVA onto nanoparticle surface in a con-
centration dependent way, promoting aggregation due to its adhesive nature[193]. The 
same behavior may be achieved when two factor are changed simultaneously, i.e., in-
creasing the amount of lipid (X1) or the amount or drug (X3). 
 Response surface analysis were plotted (Figure 4.1) based on the model polynomial 
function in a three-dimensional model depicting the effect of significant independent fac-
tors on the observed responses of particle size, PDI and EE. 
 
Parameter 
Size (Y1) PDI (Y2) EE (Y3) 
Coefficient 
p-
value 
Coefficient 
p-
value 
Coefficient 
p-
value 
Intercept 262.282 0.000 0.078 0.000 80.069 0.000 
X1 -3.009 0.334 0.005 0.150 -4.799 0.072 
X1
2 -3.431 0.157 -0.001 0.726 1.333 0.427 
X2 -7.727 0.040 0.000 0.922 -5.494 0.048 
X2
2 -3.031 0.202 0.007 0.028 1.708 0.319 
X3 4.700 0.155 -0.001 0.850 15.375 0.001 
X3
2 6.492 0.026 -0.004 0.164 4.438 0.035 
X1X2 -8.075 0.097 0.013 0.037 -7.250 0.058 
X1X3 2.307 0.585 -0.008 0.148 1.367 0.664 
X2X3 1.086 0.795 0.013 0.036 0.110 0.972 
R2 0.863 0.876 0.940 
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(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
Figure 4.1 - Response surface and counter plots of Size (a,b) PDI (b,c) EE (d,e). 
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Table 4.4 - ANOVA results from particle size, polydispersity index and entrapment efficiency 
 
Response 
 
Source 
 
DF 
 
Sum of 
squares 
 
Mean of 
squares 
 
F 
 
Fcritic 
Y1 
Model 9 19390.7000 1939.0700 30.8000 4.7700 
Error 5 3147.6980 62.9500   
Cumulative 
total 
14 22538.3980    
Y2 
Model 9 0.0027 0.0027 34.19 4.77 
Error 5 0.0004 0.0001   
Cumulative 
total 
14 0.0032    
Y3 
Model 9 2890.5920 2890.592 82.07 4.77 
Error 5 1761.0150 35220. 220   
Cumulative 
total 
14 2950.933    
 
 
Effect on entrapment efficiency 
 The EE varied from 58% (sample 4) to 95% (sample 7) for the level combinations (Ta-
bles 4.1 and 4.2, while the mean was 80.1%, according to the model intercept. The inde-
pendent factors affecting EE were the amount of surfactant (X2) and the amount of drug 
(X3
2) (p<0.05), as seen in Table 4.3. The value of the correlation coefficient (r2 0.940), in-
dicating a good correlation between observed and predicted value. 
 The amount of surfactant has a negative impact on the EE, due the negative value of 
the regression coefficient, on the contrary of the amount of drug, which both coefficients 
(linear and quadratic) presented positive signs. This might indicate a non-linearity correla-
tion between amount of drug and EE. The increase of EE in the presence of higher concen-
trations of drug was expected, as more drug is available to be entrapped. In the case of 
the surfactant level, the opposite was found, i.e., which could be explained by the parti-
tion phenomena, in which higher concentration of surfactant in the external phase might 
increase drug partition from internal to external phase, leading to drug solubilization. In-
teraction terms have non-significant effect on EE. 
 
 
4.1.2 Optimization and validation 
 
 Desirability function of STATISTICA 10 was used to get the optimized formulation. Be-
cause the PDI was always below the desired value (<0.3), the formulation optimization 
were conducted regarding particle size (closer to 250 nm) and maximum EE [143]. Upon 
assessment of several responses and comprehensive search through desirability function, 
the composition of optimized formulation was 45 mg of liquid lipid, 47 mg of surfactant 
and 18 mg of drug, which fulfill the requirements of optimized formulations. Three repli-
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cates of the checkpoint were analyzed. All the responses were considered to be in good 
agreement with the predicted values which confirmed on Figure 4.2. The optimized formu-
lation has an average size of 252 ± 9 nm and an EE 87% ± 1%, which were in good agree-
ment with the predicted values. 
Figure 4.2 - Validation of the predicted optimal results with experimental values. 
 
 
4.1.3. Physicochemical characterization of optimized NLC 
 
 Physicochemical characterization (size, polydispersity, surface potential, drug incorpo-
ration) was performed with optimized nanoparticles obtained throuhgout the experimental 
design. The results indicate that NLC size (246 ± 2 nm) increase with the incorporation of 
MTX to 252 ± 9 nm (p<0.05) and remaining homogenous, as suggested by the low values 
obtained for the PDI (<0.1). The optimized formulations exhibited a particle size below 
300 nm, suitable for systemic and topical administrations [194]. It has been described that 
PDI values below 0.3 are indicative of homogeneity of the size distribution and with mini-
mum tendency to aggregation [143]. These results are shown in Table 4.5. 
 
Table 4.5 - Particle size, PDI, ζ-potential, drug entrapment efficiency of optimized NLCs 
 Size (nm) PDI ζ-potential (mV) EE (%) 
NLC 
246 ± 2 0.09 ± 0.02 -13 ± 2  
MTX loaded-NLC  
252 ± 9* 0.06 ± 0.02 -14 ± 1 87 ± 1 
Mean ± SD (n=3), *p<0.05 
 
 In order to confirm the incorporation of MTX in the NLCs infrared spectra of free MTX, 
NLC and MTX-loaded NLC were obtained, and are presented on Figure 4.3. MTX spectrum 
shows, at 1,638 cm-1, a marked peak that indicates the presence of a C=C stretching vibra-
tion, which is characteristic of the drug molecule [195], [196]. This observation was pre-
sent also in the MTX-loaded NLC, but not in the NLC, confirming the successful incorpora-
tion of MTX in the lipid nanoparticles. The characteristic peaks from NLC were not altered 
in the MTX-loaded NLC. 
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Figure 4.3 - FT-IR spectra of raw MTX powder and lyophilized nanoparticles NLCs and MTX-loaded 
NLCs. 
 
4.1.4 Morphology of optimized NLCs 
 
 TEM studies revealed that MTX-loaded NLCs were spherical in shape with narrow size 
distribution (Figure 4.4). NLCs did not aggregated and no visible significant differences 
were observed between NLCs and MTX-loaded NLCs. The diameters of the particles ob-
served by transmission microscopy (c.a. 250 nm) are in good agreement with the data ob-
tained from dynamic light scattering (Table 4.5). 
 
Figure 4.4 - Transmission electron microscopy images of NLCs (A) and MTX-loaded NLCs (B). Amplifi-
cation of 80,000 x. 
 
 
4.1.5 Storage stability assessment of optimized NLCs 
 
 Physical stability was assessed by analyzing changes in particle size, PDI and drug content 
of NLCs stored at room temperature. For all samples no particle aggregation was found 
through visual observations, up to 4 weeks. The stability studies of MTX-loaded NLCs suggest-
ed that these nanoparticles were quite stable for a month with no significant change in the 
mean particle size and drug content (Figure 4.5). As a broad conclusion, NLCs presented good 
stability after 4 weeks with average particle size between 211.5- 264.3 nm, PDI below 0.2 and 
EE remains higher than 85%. 
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Figure 4.5 - Storage stability. Optimized MTX-loaded NLC were stored up to 4 weeks at room tem-
perature and evaluated for (A) size, (B) polydispersity and (C) drug entrapment efficiency altera-
tions. Unloaded (dark grey) and MTX-loaded (light grey). Data expressed as mean ± SD (n=3). 
 
4.1.6 In vitro methotrexate release studies of optimized NLCs 
 
 The in vitro of MTX release profile from the NLCs was investigated using a dialysis 
membrane in three conditions defined to simulate physiological, inflammatory and topical 
environments in order to simulate a systemic therapy, inflammatory and skin environments 
they are closely related present in inflammatory diseases such or rheumatic arthritis and 
PSO, respectively. In Figure 4.6 shows the release profiles obtained that were further ana-
lyzed to determine the mechanism of release using the kinetic models first-order, Higuchi, 
Peppas-Korsmeyer and Hixson-Crowell. 
 
Release simulation at physiological conditions  
 In vitro MTX release studies from the NLCs were performed at physiological conditions 
(37ºC, pH 7.4) to access the release profile upon systemic administration. The NLC formu-
lations showed an initial fast release, the release reach 30% in 2 hours, followed by a sus-
tained release up to 50% within 24 hours (Figure 4.6). The observed profile was analyzed 
by several drug release kinetic models Table 4.6, and fitted best to the Peppas-
Korsemeyer model (r2=0.9771), since the r2 value is much higher than any other kinetic 
model. In this model, the value of n characterizes the release mechanism of drug. For the 
present case n was 0.55, indicative of non Fickian diffusion, as a combination of both dif-
fusion and erosion controlled rate release [197]. 
 
Release simulation at inflammatory conditions 
 MTX is considered a reference drug for rheumatoid arthritis. We performed an in vitro 
release study simulating the inflammatory conditions  (37°C, pH 5) in order to predict the 
MTX-loaded NLC in vivo kinetics [198]. The drug release from the formulation under this 
conditions exhibited a fast initial release (40% in 2 hours) followed by a sustained release 
up to 80% within 24 hours (Figure 4.6). Data fitted best to the Peppas-Korsemeyer model 
(r2=0.9865) with an n value of 0.31, suggesting Fickian diffusion that occurs by the usual 
molecular diffusion of the drug. 
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Table 4.6 - Value of r2 obtained from the release data for different models of mechanism of 
drug release 
 
 
Model 32ºC 37ºC n 
pH 
7.4 
First order  0.2860  
Hixson-Crowell  0.2656  
Higuchi  0.5614  
Korsmeyer-Peppas  0.9771 0.545 
pH 
5.5 
First order 0.2380 0.4575  
Hixson-Crowell 0.9290 0.7679  
Higuchi 0.7096 0.8901  
Korsmeyer-Peppas 0.6389 0.9865 0.313 
 
Release simulation at skin conditions 
 Topical administration of MTX could represent an interesting approach for skin inflam-
matory diseases, as PSO. Release conditions were set to simulate the drug administration 
through the skin (32ºC, pH 5). A slow release of the MTX from the NLC was observed reach-
ing 30% after 24 hours (Figure 4.6). In this case, data fitted best to the Hixson-Crowell 
model (r2=0.9290), that describes the drug releases by dissolution mechanism that occurs 
upon a change in surface area and diameter of particles [197]. A prolonged release is of 
interest for dermal formulations as it will contribute to a sustained effect. 
 Gathering the release studies data it is possible to consider the NLCs formulations suit-
able for systemic and topical administration of MTX under physiological and inflammatory 
conditions, conferring protection and allowing drug controlled release.  
 
 
  
 
 
 
 
 
 
Figure 4.6 - MTX in vitro release from NLCs. On the left, drug cumulative release under physiologic 
(dark circles) and inflammatory environments (open squares). On the right, release simulation at skin 
environment. Data expressed as mean ± SD (n=2). 
 
4.1.7 Cytotoxicity of the optimized formulation 
 
 To assess the effect of the formulations on cell viability, a MTT assay was performed 
on L929 fibroblasts. Cells were exposed to empty NLCs and MTX-loaded NLCs up to 250 
μg.mL-1 of MTX equivalent to 27 mg.mL-1 in lipid for 24 and 48 hours. The fibroblasts toler-
ate well empty formulation as no toxicity was observed. While for MTX-loaded NLCs a 
slight effect on the viability of cells was observed in the presence of 250 μg.mL-1 MTX-
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loaded NLCs after 48 hours incubation. As for all studied conditions cell viability was above 
80% it can be stated that the formulations are not toxic to the fibroblasts Figure 4.7. The 
NLC system represents a promising option for delivery of MTX, since it did not affect cell 
viability, confirming the safety profile of the optimized delivery system. 
  
 
Figure 4.7 - Fibroblasts viability. Unloaded (dark grey) and MTX-loaded (light grey) NLCs incubated 
with fibroblasts for (A) 24 and (B) 48 hours. Data expressed as mean ± SD (n=3).  
 
 
 This lipid colloidal carrier show interesting properties for delivering MTX. Although fur-
ther studies are required in order to evaluate the therapeutic potential of the optimized 
formulation in clinically relevant models, present result demonstrated that MTX loaded 
NLCs could be a promising modality for cancer and inflammatory diseases. 
 
 
4.2 A targeted nanomedicine approach for psoriasis 
 
To implement a targeted nanomedicine approach for topical therapy of psoriasis, lipid 
nanoparticles loaded with an anti-psoritic drug (MTX) where functionalized with an anti-
body targetting the inflammatory environment (Etanercept). It is expected to produce a 
dual drug delivery systmes, where MTX act as an anti-inflammatory drug and Etanercept 
suppress overactivity of the immune system. We used a carbodiimed reaction through the 
cross linker (EDC) and the lipid DSPE-PEG-NH2. To improve its potential topical application 
a hydrogel will be prepared. Indeed, currently hydrogel enriched with nanoparticles have 
gained substantial attention as one of the most promising nanoparticulate drug delivery 
systems since it combines the characteristics of a hydrogel such their hydrophilicity, flexi-
bility, versatility, high water content with the small size of nanoparticle [182]. 
 
 
4.2.1 Physicohemical characterization 
 
 Characterization was performed with empty lipid nanoparticles or loaded with MTX, 
before and after functionalization with eternecept.  
 The results indicate that all samples presented sizes closer to 400-nm with a slight  
increase after incorporation of MTX. There are significant differences (p<0.05) in particle 
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size  when compared LNs to MTX-LNs and LNs-Etanercept to MTX loaded LNs-Etanercept 
maybe due to the decrease of inertial and hydrodynamic forces and the increase of aggre-
gate strength with decreasing particle size [199]. With respect to PDI, all of the samples 
remaining homogenous also, as suggested by the low values obtained for the PDI (<0.3) 
[143]. Zeta potential was around -28 mV and the EE was more than 83%, suggesting the 
stability of this nanoformulations. These results are shown in Table 4.7. 
 
 
 Table 4.7 - Particle size, PDI, ζ-potential, drug entrapment efficiency of lipid nanoparticles 
 Size (nm) PDI 
ζ-potential 
(mV) 
EE (%) 
 
NLC 
421.6±2.2 0.278±0.005 -29.04±0.63 
 
 
83.1 ±0.8 
 
MTX loaded-NLC 458.3±5.0* 0.280±0.007 -23.53±0.60 
NLC-Etanercept 394.0±2.9 0.256±0.007 -24.85±0.76 
 
 
MTX loaded-
NLC-Etanercept 
443.0±4.6** 0.216±0.015* -27.03±0.74 
 
88.6±1.0* 
 
SLN 396.5±4.2 0.270±0.009 -30.30±0.34  
MTX loaded-SLN 492.9±6.2* 0.268±0.001 -26.23±1.14 
 
84.2±0.2 
 
SLN-Etanercept 316.9±3.2 0.262±0.008 -30.55±0.82  
MTX loaded-
SLN-Etanercept 
356.4±2.0* 0.274 ± 0.007 -25.95 ± 1.13 88.1±0.7 
 
Mean ± SD (n=3); * p<0.5, **p<0.01 obtained with one-way ANOVA analysis, Dunett test for compari-
son amoung LNs and F-LNs.   
 
4.2.2 Morphology of targeted-lipid delivery systems 
 
 TEM and Cryo-SEM microscopies revealed that all of nanoformulations were spherical in 
shape with narrow size distribution and no visible differences between the LNs produced, 
as shown on Figures 4.8 and 4.9   
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Figure 4.8 - Transmission electron microscopy of targeted SLNs and NLCs. On top panel empty SLNs 
(A), MTX-loaded SLNs (B), SLN-Etanercept (C) and MTX-loaded SLN-Etanercept (D); bottom panel: 
empty NLCs (E), MTX-loaded NLCs (F), NLCs-Etanercept (G) and MTX-loaded NLCs-Etanercept (H); the 
scale indicated pictures is of 100 nm. Amplification: 50,000x 
 
 
 
 
Figure 4.9 - Cryo-SEM microscopy of targeted SLNs and NLCs. On top panel empty SLNs (A), MTX-
loaded SLNs (B), SLN-Etanercept (C) and MTX-loaded SLN-Etanercept (D); bottom panel: empty NLCs 
(E), MTX-loaded NLCs (F), NLCs-Etanercept (G) and MTX-loaded NLCs-Etanercept (H); the scale indi-
cated pictures is of 300 nm. Amplification: 40,000x.  
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4.2.3 Protein coupling efficiency 
 
 The efficacy of Etanercept functionalization in the different prepared NLCs (empty and 
MTX loaded) and SLNs (empty and MTX loaded) was determined by Bradford method. The 
coupling efficiency indicates the amount of protein covalently bound to the lipid nanopar-
ticle upon functionalization and is shown in Table 4.8. The results reveal that more than 
78% of Etanercept initially added was bound to the LNs. Coupling efficiency with BSA re-
vealed similar values with more than 82% of protein coupled to the LNs. 
 
Table 4.8 - Protein coupling efficiency 
 
 
 
4.2.4 Storage stability assessment  
 
 Physical stability was assessed by analyzing changes in particle size, PDI, zeta potential 
and drug content of lipid nanoparticles compared to freshly prepared nanoparticles, when 
stored at room temperature up to 6-weeks. For all samples no particle aggregation was 
found through visual observations. Data from size, PDI and surface potential analysis is 
represented on Figure 4.10 and shows no significant changes were observed upon storage. 
 Moreover, drug content remained similar to the observed upon preparation. With re-
spect to size of nanoparticles and PDI parameters, all nanoformulations presented no sta-
tistical differences in first 4 weeks. However, for SLN at 6 weeks there are differences in 
size and PDI Figure 4.10 A and B. In zeta potential parameter after incorporation of MTX at 
week 0 for MTX-loaded NLC observe a decrease of this parameter. However this result may 
be associated with wrong measurment because previously conclude that durg incorpora-
tion no affect zeta-potential of nanoparticles. Relatively at drug content no significant 
diferrences were observed. 
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Figure 4.10 - Storage stability at room temperature for lipid nanoparticles. Empty and MTX-loaded 
SLNs and NLCs prior and after Etanercept-functionalization were stored at room temperature and 
assessed for stability parameters: size (A), PDI (B), zeta-potential (C) and drug content (D) for 6 
weeks. 
 
4.2.5 In vitro methotrexate release studies  
 
 Controlled drug release was observed for all studied nanoformulations. MTX gave a 
fastest drug release in the first 24 hours: 35-40% of its initial content was released in the 
first 2 hours and a sustained release around 49-60%, after 24 hours in physiologic environ-
ment; a 20-30% of its initial content was released within 2 hours while 50% was relased 
during 24 hours in inflamatory environment; and, in skin conditions a 20-30% was released 
in the first 2 hours and then a sustained release in 24 hours of 52-60% (Figure 4.11). A simi-
lar behavior was observed for all studied nanoparticles, displaying a biphasic profile that 
was described by an initial fast drug release followed by a sustained profile. The fast MTX 
release revealed in all nanoformulations can be explained by interactions stablished be-
tween drug-lipid in the LNs. The sustained release stage may be related with a diffusion-
controlled mechanism provided by the lipid matrix: at first, MTX was effectively dissociat-
ed from the matrix and then diffuses to the external environment [200]. NLC and SLN for-
mulations did not show significant differences between them as observed in Figure 4.11. 
Only MTX-loaded NLC-Etanercept nanoparticles, under skin stimulated conditions, released 
less drug when compared with non-functionalized NLCs (Figure 4.11F). This fact can be 
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explained due to structural integrity conferred by protein coupling (Etanercept) that might 
lead to a double barrier effect interfering negatively in drug diffusion [201].  
 
Figure 4.11 - MTX in vitro release from targeted lipid nanoparticles. The assays were conducted 
under simulated physiologic (37ºC, pH 7.4 – A and B), inflammatory (37ºC, pH 5 – C and D) and skin 
(32ºC, pH 5 – E and F) environments. Data expressed as mean ± SD (n=2) represents MTX-loaded SLN 
(open squares), MTX loaded SLN-Etanercept (closed squares) on graphs A, C and E; and MTX-loaded 
NLC (open circle), MTX-loaded NLC-Etanercept (closed circle) on graphs B,D and F .     
 
 
  The release profiles of the studied formulations were evaluated by fitting the experi-
mental data to different kinetic equations (zero-order, first-order, korsemeyer-peppas, 
Hixson-Crowel and Higuchi equation) which are widely used in determining the release kinet-
ics of lipid nanoparticles. The best kinetics of release profile of nanoparticles was found fol-
lowing korsemeyer-peppas model having the highest value of correlation coefficient r2   (Table 
4.9 and Table 4.10). 
 The parameter “n” in the Korsmeyer-Peppas equation is related to the mechanism of re-
lease of the drug, i.e. if the exponent n < 0.43, then the drug release mechanism is Fickian 
diffusion, if 0.43 < n < 0.85, then it is non-Fickian or anomalous diffusion and an exponent 
value is 0.85 or greater is indicative of Case-II Transport or typical zero-order release [209, 
210].  
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 In this case all formulations give a value of n below 0.45, so their release mechanism 
followed a Fickian diffusion. 
 This model, also known Power law has been used to describe the drug release from 
several different pharmaceutical modified release dosage forms [204]. 
 
Table 4.9 - Value of r2 obtained from fit of different mathematical models of mechanism of drug 
release to the MTX release data from the SLNs nanoformulations 
  Mathematical model MTX-SLN 
MTX-SLN-
Etanercept 
 
pH 7.4 
First order 0.4951 0.6233 
37ºC 
Hixson-Crowell 0.7104 0.7662 
Higuchi 0.5438 0.7059 
Korsmeyer-Peppas 
n 
0.8275 
0.21 
0.8990 
0.31 
pH 5.5 
First order 0.8742 0.8645 
Hixson-Crowell 0.9373 0.9316 
Higuchi 0.9261 0.7854 
Korsmeyer-Peppas 
n 
0.9502 
0.45 
0.9785 
0.29 
32ºC pH 5.5 
First order 0.8979 0.9246 
Hixson-Crowell 0.9564 0.9825 
Higuchi 0.9340 0.9246 
Korsmeyer-Peppas 
n 
0.9857 
0.39 
0.9941 
0.37 
 
Table 4.10 - Value of r2 obtained from fit of different mathematical models of mechanism of drug 
release to the MTX release data from the NLCs nanoformulations 
  Mathematical model MTX-NLC 
MTX-NLC-
Etanercept 
 
pH 7.4 
First order 0.5615 0.5228 
37ºC 
Hixson-Crowell 0.7138 0.7415 
Higuchi 0.5766 0.5863 
Korsmeyer-Peppas 
n 
0.9137 
0.21 
0.9275 
0.23 
pH 5.5 
First order 0.8989 0.8603 
Hixson-Crowell 0.9582 0.9546 
Higuchi 0.9182 0.8676 
Korsmeyer-Peppas 
n 
0.9865 
0.45 
0.9857 
0.38 
32ºC pH 5.5 
First order 0.8989 0.8603 
Hixson-Crowell 0.9582 0.9546 
Higuchi 0.9182 0.8676 
Korsmeyer-Peppas 
n 
0.9865 
0.45 
0.9857 
0.38 
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4.2.6 Cytotoxicity of targeted nanoparticles 
 
 To evaluate the effect of the functionalization and the other nanoformulations on cell 
viability, a MTT assay was performed on L929 fibroblasts and HaCaT KC (Figure 4.12).  
 
Figure 4.12 - L929 fibroblasts and HaCaT keratinocytes cells. Amplification of 40x. 
 
Cells were exposed to empty LNs and MTX-loaded LNs with or without functionalization 
up to 250 μg.mL-1 of MTX equivalent to 5 mg.mL-1 in lipid for 24 hours. Free MTX was 
appied in HaCaT cell line and was observed a decrease on cells viability to 75% with 250 
μg.mL-1.  
 The fibroblasts and HaCaT tolerate well empty formulation as no toxicity was observed  
After incoporation of MTX in the presence of 250 μg.mL-1 cell viability was reduced for 80% 
in both cell lines after 24h.  
 After Etanercept functionalization in nanoparticles loaded with MTX a slight effect on 
the viability of cells was observed and this parameter was reduced for 70%. As for all stud-
ied conditions cell viability was above 80% it can be stated that these nanoformulations 
and its functionalization is no toxic for both types of cells. So, these lipid system repre-
sents a promising option for delivery of MTX, since concentrations of MTX closer to 100 
μg.mL-1 no affect cell viability, confirming the safety profile of the delivery system. 
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Figure 4.13 - L929 fibroblasts and HaCaT keratinocyte cell viability. Unloaded LNs (white bar), MTX-
loaded LNs (light grey bar), Etanercept-functionalized LNs (squares bar), and MTX-loaded LNs-
Etanercept (black bar) were incubated with fibroblasts (A, B) and keratinocytes (C, D) for 24 hours. 
The dotted line at 80% represents the viability limit defined. Data expressed as mean ± SD (n=3).  
 
 
4.2.7 Rheological properties of hydrogel-enriched nanoparti-
cles  
 
In this work, we tested four different concentrations of Carpobol 934 (0.5; 1; 1.5 and 
2% (w/w)) corresponding to 0.125, 0.250, 0.375 and 0.5 g of Carbopol 934® for 25 g of hy-
drogel. For all of these concentrations all hydrogels presented a clear, glossy and homoge-
neous aspect. However as LNs are liquid we had to exclude carbopol with lower concentra-
tions, i.e., at 0.5 and 1% (w/w). In order to choose between Carbopol 1.5 and 2% we test-
ed the addition of 10 mg of empty LNs. Upon the hydrogel enriched-nanoparticles prepara-
tion the rheological properties, namely shear stress and viscosity, were studied. The flow 
curves shown in Figure 4.14. A represent the two different concentrations of carbopol (1.5 
and 2%). The different curves relate the measurement of shear stress (Pa) with increasing 
shear rate (1/s), and measurement of shear stress (Pa) with decreasing shear rate (1/s). It 
is possible to observe that ascending and descending curve of each hydrogel practically did 
not overlap, which indicates the existence of thixotropy (reflects a degradation behaviour 
of the semisolid structure after application of the shear stress and posterior returns to the 
initial apparent viscosity  [205].  
Furthermore, we can see in Figure 4.14 that two differente carbopol concentrations 
possess pseudoplastic characteristics, as the viscosity decreases with the increase of shear 
rate. Pseudoplastic properties are a desired of topical systems because at high shear 
stresses the material will flow rapidly [205]. For LNs incorporation we choose the Carbopol 
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1.5% due to its better spreadability properties as observed in the Figure 4.14 with a lower 
value of shear stress. 
 
Figure 4.14 - The flow curves of carbopol gel placebo (A) Shear stress and (B) viscosity  in blue 
Carbopol 1.5% and in red 2% of Carbopol. 
 
 Hydrogel 1.5% carbopol was enriched with 6 mg of free MTX and the rheological prop-
erties are shown in Figure 4.15. It is possible to observe that the hydrogel enriched with 
MTX did not retained thixotrophy. Flow curves are totally overlapped Figure 4.15A which 
indicates that MTX completely changes the hydrogel structure with respect to its 
thixotrophy. This results hampers the use of Carbopol 1.5% as carrier of free MTX in topical 
applications because it changes the thixotropic properties of the hydrogel base [188].  
 
Figure 4.15 - The flow curves of carbopol gel enriched with MTX. (A) Shear stress and (B) viscosity in 
green Carbopol 1.5% and in blue Carpobol 1.5% - enriched MTX. 
 
 
 The rheological behavior of hydrogel carbopol 1.5%, enriched with empty and MTX-
loaded SLN or NLC nanoparticles is presented in Figure 4.16. For all the hydrogels enriched 
with the LN produced it is possible to observe that curves did not overlap (Figure 4.16 
A,B), which indicates the existence of thixotropy such as observed with carbopol placebo 
gel . The hysteresis loop reveals that the area of thixotropy is similar for all formulations. 
 However, empty and MTX-loaded NLCs seemed to present a greater area of thixotropy 
when compared with hydrogel enriched with SLNs, which means that NLCs containing hy-
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drogels are easily spreadable in the skin. This result is also supported by the yield stress 
values (Table 4.11).  
 
Table 4.11 - Yield stress values for all hydrogels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The intersection on the stress axis is then taken as the yield stress, the assumption be-
ing that any stress below this is insufficient to cause the sample to flow. In general, lower 
values of the yield stress increase spreadability. Data of yield stress shows that hydrogel 
with Carbopol 1.5% have lower values of yield stress when compared with hydrogel 
carbopol 2%. Also, hydrogels enriched with NLC have lower yield stress values compared to 
SLN, so could represent the best choice for topical administration. For hydrogels contain-
ing MTX-loaded LNs, the yield stress value increases in comparison to the empty LNs, 
meaning that at is necessary more shear in the gel when drug is present, to cause the gel 
to flow. Furthermore, it was observed that all hydrogels mantained their pseudoplastic 
properties (Figure 4.16).  
 
 
 
Hydrogel Yield stress(τ0-Pa) 
Carbopol 1.5% 158.3 
Carbopol 2% 191.0 
SLN 198.4 
NLC 176.2 
MTX loaded SLN 248.2 
MTX loaded NLC 185.8 
SLN- BSA 240.5 
NLC- BSA 198.4 
MTX loaded SLN-BSA 207.2 
MTX loaded NLC-BSA 169.6 
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Figure 4.16 - Flow curves for hydrogel enriched LNs. (A) shear stress and (B) viscosity top images: in 
purple SLN and in red MTX loaded SLN; bottom images: purple NLC and orange MTX loaded NLC. 
 
 Figure 4.17 shows the pseudoplastic properties of hydrogels enriched with functional-
ized LNs. Results indicated that all of formulations maintaining thixotropy. Functionalized 
NLCs exhibit lower yield stress values compared to functionalized SLNs, as observed with 
the non-targeted LNs. Hydrogel enriched with functionalized NLCs represent a good choice 
for topical applications due to lower values of yield stress (Table 4.11), that is, higher 
spreadability. The hydrogels incorporating emtpy nanoparticles have higher spreadability 
than when MTX is present, as indicated by a higher area of thixitropy. The presence of 
drug, lowers these parameter translating a decreased ability of these two types of hydro-
gels to return of their initial properties, after application of shear stress. This could be 
explained because functionalization increase the viscosity of nanoparticles due to the ag-
gregation of protein [213, 214]. 
 
Figure 4.17 - Flow curves for LNs. (A) shear stress and (B) viscosity Top images: blue with SLN-BSA 
and green wit MTX loaded SLN-BSA and bottom images: ligth blue with NLC-BSA and orange with MTX 
loaded NLC-BSA. 
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4.2.7.1 Storage stablity of hydrogel enriched nanoparticles  
 
 
 Storage stability of hydrogel and -hydrogel enriched nanoparticles was assessed after 2 
weeks of preparation. All of hydrogels appeared transparent, glossy and uniform within 
this period of time. Furthermore, their rheological parameters were measured in order to 
investigate any changes in the pseudoplastic properties and thixotropy. Figure 4.18 shows 
that no differences were observed in the hydrogel carbopol 1.5 and 2% between 0 an  d 2 
weeks storage at room temperature, as all curves are practically overlapped. 
Figure 4.18 - The flow curves of carbopol gel placebo (A) Shear stress and (B) viscosity in blue Carbopol 
1,5% and in red 2% of Carbopol at 0 and 2 weeks. 
 
 Rheological measurements after 2 weeks in hydrogels enriched LNs (with and without 
drug, functionalized or not) confirmed the reported values of low viscosity at week 0. Flow 
curves illustrated in Figure 4.19 and Figure 4.20 for LNs and functionalized LNs, respec-
tively, revealed similar psedoplastic behaviour as showed in week 0 as all formulations 
presented thixotropy, reversible variation of viscosity. However, in shear stress along the 
time, we could see a small decrease of this value in two weeks that means that it is neces-
sary small shear in gel to cause the gel to flow. This behaviour can be explained by the 
existence of certain internal structures that change with flowing; certain particles aggre-
gates, formed by hydrogen bonds or van der Waals interactions, that could brake and pro-
mote a small decrease in its consistency [212, 215]. For these reasons it seems that 
altough the formulations presented a small decrease in shear stress they remained a good 
option for topical application, due to pseudoplastic and thixotropy properties.  
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Figure 4.19 - Flow curves for hydrogels enriched LNs. (A) shear stress and (B) viscosity Top images:  
SLNs and bottom images with NLCs after 2 weeks of storage. 
 
 
 
Figure 4.20 - Flow curves for hydrogels containing functionalized LNs. (A) shear stress and (B) viscosity 
Top images:  SLNs-BSA as MTX loaded SLNs-BSA after 15days and bottom images with NLCs-BSA and MTX 
loaded NLCS-BSA. 
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4.2.8 Skin permeation studies  
 
 One of most important in vitro characterization study that a topical formulation can be 
subjected to is a permeation study (also referred to as penetration study) and in this case 
its crucial that this system mimics the psoriasis environment [209]. 
 The aim of present section was to investigate topical deliver of both MTX and 
Etanercept drugs using lipid delivery systems. To assess in vitro MTX skin penetration, the 
Franz diffusion cells were used, as described on section 3.15. Diffusion rates of drug 
through the epidermis can also be influenced by membrane components, enzymes and 
transporters and also to be affected by surface charge, properties of the nanomaterial, 
drug-loading efficiency, mode of application and hydrogen bonding ability [95, 188, 217].  
 Figure 4.21  shows the MTX skin penetration as free drug and when incorporated in the 
lipid nanoparticles (functionalized or not). After 8 hours the amounts of MTX that perme-
ated through pig skin were: 1.7 ± 0.1%, 4.8 ± 0.2%, 3.1 ± 0.01%,  2.97 ± 0.03% and 2.17 ± 
0.01% for free MTX, MTX loaded -SLNs, - NLCs, -SLN-BSA and –NLC-BSA, respectively. The 
diferences between free drug and loaded nanoparticles can be explained because nanopar-
ticles improve MTX penetration into the skin, as previously described [211]. From this, it 
can be concluded that both LNs play important role in controlling the MTX delivery and 
targeting through the skin. Functionalization with protein in both LNs acts as double barri-
er effect for drug diffusion through the structural integrity conferred by BSA  coupling, 
therefore decreasing drug penetration profile [168]. 
 
Figure 4.21 - MTX penetration through pig skin during 8 hours. 
 
 Furthermore we performed  skin permeation studies with the  hydrogel enriched with LNs. 
The drug flux rate through the skin during 8 hours was determined and listed on Table 4.12. 
In general, permeation profile is as follow: LNs> Hydrogel enriched with LNs.  
 In the case of hydrogel enriched with LNs the flux value decreased about 10 times for MTX 
loaded -SLNs, - NLCs, -SLN-BSA and –NLC-BSA, when compared to MTX loaded LNs and MTX 
loaded-BSA. LNs embedded hydrogel exhibited smaller amount of drug permeation. These 
results was also observed by other authors [198, 219, 220]. This fact could be explained  due 
to the mucoadhesive properties of hydrogel that enhance the retention time of  MTX [213]. 
 However, when comparing free MTX permeation amounts with hydrogel loaded with 
equivalent amount of MTX, we observed that the latter could permeate a higher quantity of 
drug. This result can be explained through rheological properties described in section 4.2.7 
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 Probably, free MTX changes the hydrogel structure with lost of consistency that could fa-
cilitate the drug penetration in skin.  
 
Table 4.12 - MTX flux through pig ear skin upon 8 hours 
Formulation code Flux (μg/cm2/h) 
Free MTX 0.71 ± 0.11 
H MTX 1.23 ± 0.05 
MTX-SLN 2.60 ± 0.10 
H MTX-SLN 0.26 ± 0.01 
MTX-SLN-Etanercept 1.76 ± 0.11 
H MTX-SLN-Etanercept 0.13 ± 0.01 
MTX-NLC 1.79 ± 0.09 
H MTX-NLC 0.16 ± 0.01 
MTX-NLC-Etanercept 1.04 ± 0.13 
  H MTX-NLC-Etanercept 0.14 ± 0.01 
 
 
 It is described in the literature that when the skin barrier is compromised, nanoparti-
cle penetration might be considerably enhanced. In psoriasis, with inflammation and KC 
hyperproliferation, there are some alterations of the SC that may favor the penetration of 
nanoparticles in psoriatic lesions [87]. 
 Interestingly, NLC presents increased retention of MTX. So, there is no consensus on 
the use of NLC instead of SLN in order to increase skin penetration of certain drugs [214].  
 
 
Functionalization with Etanercept allowed to obtain a targeted dual therapy and it was 
performed by a carbodiimide reaction. Both of proteins, BSA is a model protein usually 
used in replacement of more expensive proteins, as is the case of Etanercept [76, 83, 175]. 
 In the skin permeation studies, we used BSA to functionalized the LNs instead of 
Etanercept since both are proteins with similar sizes (< 10 nm) [175, 222].  
 In order to evaluate if protein-bound to the nanoparticle is able to cross the skin barri-
er, we quantify the amount of BSA that permeate ear pig skin. Data indicated that 10-20% 
BSA could enter in the skin in the first 8 hours in contact with skin. So, we could infer that 
functionalized nanoparticles are suitable for topical application in treatment of psoriasis 
achiveing a dual therapeutic effect.  
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Chapter 5 - Conclusion 
 
 
 Psoriasis (PSO) is a commom chronic immune-mediated inflammatory disorder associ-
ated with abnormal differentiation and hyperproliferation of epidermal keratinocytes (KC) 
affecting 2–3% of the population.  The stratum corneum (SC) is a physical barrier to most 
substances that come in contact with the skin. The success of dermatological products and, 
in this case, topical therapy of PSO, depends on the capability of the drug to overcome 
this barrier and to penetrate through skin in sufficient therapeutic amounts. Bearing that 
in mind, several systems have been developed to overcome this barrier. Among those 
nanocarriers, particulate lipid based nanocarriers such as SLN and NLC exhibit many fea-
tures for dermal application of cosmetic and pharmaceutical products, such as, the con-
trolled release and targeting of drugs, occlusion associated with penetration enhancement, 
increase of skin hydration and excellent tolerability. So, in this work SLN and NLC were 
chosen as systems to incorporate and deliver the MTX into the skin. 
The first aim of this work consisted in the optimization of NLCs loaded with MTX for 
the treatment of psoriasis. In order to reduce the number of experiments and cost we per-
formed a experimental design, full factorial and Box-Behnken design to improve the pro-
duction of a particular system with certain properties. This study was able to evaluate the 
most important parameters in the production of NLC using Witepsol®E85, Miglyol®812 and 
PVA. With this conditions the amount of drug and surfactant have more impact in three 
responses (size, PDI and entrapment efficiency) assessed. NLC containing MTX were pro-
duced successfully by ultrasonication method with size closer to 200-300 nm, zeta poten-
tial values, in absolute values, were high enough to assure a good electrostatic stabiliza-
tion, higher values of drug content, at least one month stable stored at room. Morphologi-
cal investigations showed that all nanoparticles exhibit a spherical shape and a smooth 
surface independently of their composition. After analyzing the physical and chemical sta-
bility of loaded LNs, in vitro drug release and were performed and can be concluded that 
MTX release into NLCs revealed a fast initial drug release followed by a sustained drug re-
lease. As for all studied conditions cell viability was above 80% it can be stated that the 
formulations are not toxic to the fibroblasts and this NLC system represents a promising 
option for delivery of MTX, since it did not affect cell viability, confirming the safety pro-
file of the optimized delivery system. 
 
 
 In short conclusion of the first approach of this work, the lipid colloidal carrier optimized 
shows interesting properties for delivering MTX. Although further studies are required in order 
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to evaluate the therapeutic potential of the optimized formulation in clinically relevant mod-
els, present result demonstrated that MTX loaded NLCs could be a promising platform for oth-
er inflammatory diseases and even cancer therapy. 
 
 The second aim of this work was to develop a targeted nanomedicine appoach for 
treatment of psoriasis. NLCs and SLNs were produced by ultrasonication method. Func-
tionalization with Etanercept in order to obtain a dual target therapy. All 
nanoformulations present size closer to 400 nm, zeta potential values, in absolute values, 
were high enough to assure a good electrostatic stabilization and high values of drug con-
tent. Furthermore, morphological investigations by TEM and Cryo-SEM showed that all na-
noparticles exhibit a spherical shape and a smooth surface independently of their composi-
tion. The physical and chemical stability of all formulation at 6 weeks was assessed. In 
vitro drug release and skin permeation studies were performed and can be concluded that  
MTX release from LNs  reveal similar behaviour: fast initial drug release followed by a sus-
tained drug release.This type of release is interest for drugs encapsulated in cosmetics 
that will thus have a more sustained and prolonged effect, as desired for anti-psoriasis 
therapy.  Furthermore, we produced a hydrogel (Carbopol 934®) enriched with empty LNs 
MTX loaded LNs, F-LNs and MTX loaded F-LNs  in order to assess its rheological properties, 
the ability to be applied in topical admnistration of MTX and their skin permeation behav-
iour. Rheological tests performed showed that all the designed formulations had a non-
Newtonian, pseudoplastic, thixotropic behavior, suggesting that they are suitable for topi-
cal drug delivery with a small decrease of it consistency in 2 weeks. However this fact 
could be overcomed with a preservative. The rheological results showed that hydrogels 
enriched with LNs are good options to be applied in topical administration. Skin permea-
tion assays demonstrated that, mimicking physiological values and temperature, LNs load-
ed with MTX have good levels of MTX and protein penetration through pig ear skin with 
small decrease of MTX permeation when LNs were embedded in the hydrogel.  
Nevertheless, MTX incorporated in both LNs has already proved to gather several opti-
mal characteristics that indicate that the proposed novel formulation can be an excellent 
administration MTX in a topical away for psoriasis therapy. 
 
Future work, and before concluding about the real potentiality of these 
nanoformulations and the possibility of actually using these nanoparticles in a topical 
therapy for psoriasis, several experiments still need to be performed. DSC investigations 
should be performed to evaluate the possible polymorphic modifications that can occur in 
storage. To assess the behaviour of these systems in psoriatic environment we could per-
formed permeation studies with psoriatic human skin and evaluate cell viability under in-
flammatory conditions. The hydrogels enriched LN should be characterized for their physi-
cochemical properties such as color, odor and pH, mean size, zeta potential, loading effi-
ciency, polymorphism and in vitro release. Furthermore hydrogel optimization (amount of 
carbopol, quantity of MTX and protein) should be conducted to improve the skin permea-
tion results.  
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